Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019

GBD 2019 Tobacco Collaborators*

Summary

Background Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco control efforts nationally and globally.

Methods We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, providing more comprehensive estimates of the health effects of smoking than previously available.

Findings Globally in 2019, 1·14 billion (95% uncertainty interval 1·13–1·16) individuals were current smokers, who consumed 7·41 trillion (7·11–7·74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had decreased significantly since 1990 among both males (27·5% [26·5–28·5] reduction) and females (37·7% [35·4–39·9] reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers from 0·99 billion (0·98–1·00) in 1990. Globally in 2019, smoking tobacco use accounted for 7·69 million (7·16–8·20) deaths and 200 million (185–214) disability-adjusted life-years, and was the leading risk factor for death among males (20·2% [19·3–21·1] of male deaths). 6·68 million [86·9%] of 7·69 million deaths attributable to smoking tobacco use were among current smokers.

Interpretation In the absence of intervention, the annual toll of 7·69 million deaths and 200 million disability-adjusted life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large implementation gap remains for tobacco control. Countries have a clear and urgent opportunity to pass strong, evidence-based policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens.

Funding Bloomberg Philanthropies and the Bill & Melinda Gates Foundation.

Introduction Over the past 30 years, more than 200 million deaths have been caused by smoking tobacco use, and annual economic costs due to smoking tobacco use exceed US$1 trillion.1 With more than 1 billion current smokers globally in 2019, these numbers are likely to increase over the coming decades. The enormous health and economic consequences of the global tobacco epidemic make tobacco control a clear and urgent public health priority.1 Effective implementation and enforcement of tobacco control policies and interventions can both increase healthy life expectancy and decrease health-care costs.1,2 Despite the clear benefits, progress in tobacco control has varied substantially across countries.

The first international public health treaty, the WHO Framework Convention on Tobacco Control (FCTC), entered into force and became an international binding law in 2005.3 Consensus on the importance of tobacco control led 182 countries to ratify the treaty, which outlines a suite of recommended demand-reduction tools. These tools include reducing affordability through taxation, passing smoke-free laws, mandating health warnings on packaging, and banning tobacco advertising, promotion, and sponsorship.4 15 years after the FCTC entered into force, a large implementation gap remains for tobacco control. WHO has monitored the implementation of the FCTC articles using the MPOWER framework for more than a decade.5 Over this period, only two countries, Brazil and Turkey, have implemented all the demand-reduction policies included in MPOWER at their highest level.6 Nonetheless, progress has been made in expanding coverage of best-practice policies,
The importance of smoking tobacco use as a risk factor has resulted in a long history of estimating its prevalence and health effects using a variety of epidemiological methods. WHO produces biennial updates to estimates of prevalence of smoking tobacco use and the status of tobacco control policies around the world. The most recent global analysis of the burden of disease attributable to smoking was published on the basis of results from The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2015.

This study, which is based on results from GBD 2019, updates and improves on previous estimates of the prevalence of smoking tobacco use and attributable disease burden. Compared with the GBD 2015 smoking prevalence and disease burden study, we have included more than 800 additional data sources on prevalence of smoking. In terms of methods, we developed and implemented a new unified approach to estimating the disease burden attributable to smoking tobacco use that addresses limitations of previous methods with direct estimation for all 36 causally linked health outcomes and reflecting dose-response associations among both current and former smokers. We estimated new continuous exposure with the number of countries implementing at least one best-practice policy increasing from 43 in 2007 to 136 in 2018.9

The global importance of non-communicable diseases has led to their inclusion at the forefront of global progress targets, including a goal of 25% reduction in premature mortality from non-communicable diseases by 2025 outlined in the WHO global non-communicable disease monitoring framework and a third reduction by 2030 included in the UN Sustainable Development Goals (SDGs).10,12 Tobacco control has been identified as a crucial and necessary part of reaching these goals, with one in six non-communicable disease-related deaths being attributable to smoking tobacco use.11–15 As countries work towards meeting global progress targets for reducing the prevalence of smoking tobacco use and premature mortality from non-communicable diseases, timely data on the prevalence of smoking tobacco use and attributable disease are necessary to guide effective policy and planning.16–17

The public health significance of smoking tobacco use has resulted in a long tradition of estimating patterns of smoking tobacco use and its health effects.18–21 Estimates of the attributable burden of smoking tobacco use have been included in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) since its initial publication in 1997.11 Previous studies estimating the attributable burden of tobacco smoking have combined indirect estimation using the Smoking Impact Ratio method for cancers and chronic obstructive pulmonary disease, which uses observed lung cancer mortality to indirectly estimate the disease burden attributable to tobacco smoking, with direct estimation using lagged prevalence of daily smoking tobacco use for cardiovascular and circulatory diseases and all other health outcomes.22,23,24 For health outcomes modelled using daily prevalence, risks among occasional smokers and former smokers were not included, and methods did not reflect well described dose-response associations between smoking intensity and risk of disease. For the health outcomes modelled using the Smoking Impact Ratio method, reliability was low in countries with either sparse or poor quality data on lung cancer mortality and in countries with other important competing risks for lung cancer, such as air pollution.

The objective of this study, which is part of GBD 2019, was to update and improve previous estimates of global trends in the prevalence of tobacco smoking and tobacco smoking-attributable disease for 204 countries and territories, by age and sex, from 1990 to 2019. Using new methods and new data, we aimed to provide novel insights into patterns of smoking intensity and their association with health outcomes that are directly relevant to guiding tobacco control efforts nationally and globally. This manuscript was produced as part of the GBD Collaborator Network and in accordance with the GBD Protocol.
Methods

Overview
As part of GBD 2019, we estimated the burden of disease attributable to smoking of tobacco using the comparative risk assessment framework for 204 countries and territories, by age and sex, and from 1990 to 2019. We used direct estimation methods for 36 causally linked health outcomes that show dose-response associations among both current and former smokers. Here, we summarise the key analytical steps: estimating prevalence among both current and former smokers. Here, we used direct estimation methods for 36 causally linked territories, by age and sex, and from 1990 to 2019. We used the estimated age-sex pattern, which varied by location and year, to split aggregated data, a process that also allowed us to propagate uncertainty in the age-sex pattern. These methods have been previously published, and full details are in appendix 1 (pp 13, 20).

We used spatiotemporal Gaussian process regression (ST-GPR) to model prevalence of both current and former smoking tobacco use (appendix 1 p 21). This modelling approach has been used extensively in GBD to estimate time-varying risk factors. Briefly, the model was estimated in three stages. First, the level and trend were set in countries using linear regression based on covariates. Next, the first-stage estimates were adjusted by adding residuals with decaying weights across time, age, and location. Finally, the second-stage estimates were used as the prior in Gaussian process regression, which further refined the model fit and incorporated both data and model uncertainty. 1000 draws from the posterior distribution were retained and used for analysis. We report results with the 95% uncertainty interval (UI) of estimates based on the 2.5th and 97.5th percentile of draws.

Prevalence of smoking tobacco use
We systematically identified and extracted data from 3625 nationally representative surveys, including both multinational and country-specific surveys, covering 200 of the 204 countries and territories included in the analysis. 171 (86%) of 200 countries had at least five surveys for the period 1980–2019, and 141 (71%) countries had data available from 2015 or later. Data for 1980–89 were used to inform trend times, but are not reported in the results. For countries without data, estimates were entirely based on models. We extracted data for individuals aged 10 years and older, and used data on individuals aged 10–14 years to inform model estimates; however, we report prevalence among individuals aged 15 years and older. Additional information on identification of sources, inclusion criteria, and data extraction are in appendix 1 (pp 11–12). A complete list of data sources used in our analysis is available through the Global Health Data Exchange (GHDx).

To ensure that all data included in the model were comparable, and to prevent compositional bias from affecting our estimates, we used two key data processing steps. First, we used linear regression to adjust data from surveys that only reported non-reference case definitions. Our reference case definitions were current use of any smoked tobacco product on a daily or occasional basis, and former use of any smoked tobacco product. We included all smoked tobacco products—eg, cigarettes, pipes, cigars, shisha, bidis, kreteks, and other local smoked tobacco products. We did not include smokeless tobacco, electronic cigarettes (also known as e-cigarettes), vaping products, or heated tobacco products. Risks from chewing tobacco and second-hand smoke are included as other risk factors in GBD and are outside the scope of this study.\textsuperscript{26}

Second, we split data reported in aggregated age groups or as both sexes combined into our standard 5-year age-sex groups. To estimate an age-sex pattern that reflects observed spatial and temporal variation, we estimated a preliminary prevalence model using only data available in our standard age-sex groups. We then used the estimated age-sex pattern, which varied by location and year, to split aggregated data, a process that also allowed us to propagate uncertainty in the age-sex pattern. These methods have been previously published, and full details are in appendix 1 (pp 13, 20).

Exposure distribution
Estimates of prevalence of current and former smoking tobacco use define the full population at risk, but risk of disease varies within these groups on the basis of intensity of smoking and length of time since cessation. To incorporate these differences in risk in our estimation framework, we modelled continuous exposure distributions among both current and former smokers. Among current smokers, we estimated two distributions: cross-sectional cigarette-equivalents of tobacco per smoker per day and cumulative pack-years across their lifetime. Among former smokers, we estimated the distribution of the number of years since cessation. To account for heterogeneity in smoked tobacco products, we use a standard unit of cigarette-equivalents of tobacco. We converted non-cigarette tobacco products to cigarette-equivalents on the basis of amount of tobacco (in g), assuming 1 g of tobacco per cigarette. Estimates of cigarette-equivalents consumed per smoker per day combine two sources of information: self-reported smoking patterns from household surveys and supply-side data on country-level consumption available from the Food and Agriculture Organization of the UN (1961–2013), the US Department of Agriculture (1960–2005), and Euromonitor (2002–17). Details on the modelling process for the supply-side data and approach to integrating the two sources of information are in appendix 1 (pp 22–23).

Using estimates of cigarette-equivalents per smoker per day by location, age, and sex from 1960 to 2019,
along with estimates of the distribution of initiation age, we reconstructed individual smoking histories on the basis of birth cohort smoking patterns to estimate population-level distributions of pack-years consumed. This approach is crucial to estimation of the burden of health outcomes that are linked to long-term cumulative exposure, because assumptions of constant consumption on the basis of cross-sectional patterns result in underestimation of risk at older ages and overestimation of risk at younger ages.

Where available, we extracted age of cessation or years since cessation from surveys to estimate a distribution of years since cessation among former smokers. Distributions of years since cessation, cigarette-equivalents per smoker per day, and age of initiation were based on an ensemble of underlying distribution shapes, parameterised by means (estimated using ST-GPR) and SDs (predicted from means using linear regression). An expanded description of the ensemble distribution strategy is in appendix 1 (p 24).

Dose-response risk curves
Previous estimates of smoking-attributable burden in GBD relied on dichotomous exposures, despite well documented dose-response associations. To address this limitation, we estimated dose-response risk curves for both current and former smokers for 36 health outcomes using meta-regression (appendix 1 p 26). This process involved an extensive systematic review, covering 71996 total search string hits, from which 902 prospective cohort and case-control studies were found to be eligible and from which data were extracted (Preferred Reporting Items for Systematic reviews and Meta-Analyses [PRISMA] diagrams for each outcome are in appendix 1 [pp 31–66]). For cancers and chronic obstructive pulmonary disease, we used pack-years as the exposure, allowing risk to reflect both duration and dose (cigarette-equivalents per day) of exposure. For cardiovascular and circulatory diseases and all other health outcomes, we used cigarette-equivalents per smoker per day as the exposure among current smokers, because dose is generally thought to be more important than duration of exposure for these health outcomes. We used the Disease Modelling Ordinary Differential Equation (DisMod ODE) solver to fit non-linear Bayesian meta-regressions for each health outcome.\(^{9,10}\) Due to a paucity of data on relative risks among individuals younger than 30 years, we attributed outcomes to individuals aged 30 years and older, an approach consistent with previous GBD studies.

Among former smokers, risk decreases with an increasing number of years since cessation, but the level of risk also depends on previous smoking history. To control for differences in smoking history across the populations included in the meta-regressions, we adjusted reported relative risk estimates to standardise the risk at the time of cessation (appendix 1 pp 26–28).\(^{9,10}\)

Population attributable fractions
Inputs to estimation of PAFs included prevalence of current and former smoking tobacco use, continuous exposure distributions, relative risks, and the theoretical minimum risk exposure level. For smoking tobacco use, the theoretical minimum risk exposure level is never smoking. The PAF equation is specified in appendix 1 (p 28). Because the risk reduction curves for former smokers must account for two dimensions—years since cessation and intensity of smoking before cessation—we scaled the risk reduction curves for former smokers to match their starting relative risk (when years since cessation equals zero) to the exposure-weighted relative risk among current smokers in that population. We combined global dose-response risk curves with country-year-age-sex-specific continuous exposure distributions so we could capture differences in risk across countries that result from heterogeneous smoking patterns. Exposures were lagged on the basis of the average length of follow-up across studies included in the meta-regressions (appendix 1 p 28). We calculated attributable burden by multiplying PAFs with cause-specific deaths by location, year, age, and sex, available from GBD 2019.\(^{11}\) Using the distributive property of PAFs, we also partitioned out smoking-attributable deaths by exposure categories.\(^{9,10}\)

Using our PAF estimates, we calculated the number of smoking attributable deaths, disability-adjusted life-years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs). We further calculated the ratio of YLLs to YLDs by country and examined associations of this ratio with Socio-demographic Index level. For analyses by country income level, we used World Bank income groups.

We did all analyses using R (versions 3.1–3.6) and Python (version 2.7).

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results
Globally, there were 1·14 billion (95% UI 1·13–1·16) current smokers in 2019. Age-standardised prevalence of current use of smoking tobacco among individuals aged 15 years and older was 32·7% (32·3–33·0) among males and 6·62% (6·43–6·83) among females. Age-standardised prevalence among males aged 15 years and older ranged from 7·33% (6·56–8·20) in Peru to 64·6% (62·7–66·6) in Timor-Leste, and among females from 0·696% (0·517–0·906) in Eritrea to 42·3% (36·5–48·4) in Greenland (table). Smoking prevalence exceeded 20% among males in 151 countries and among females in 42 countries (table). Among individuals aged 15 years and older, countries with the highest prevalence of smoking tobacco use among males were mostly in Asia.
and Oceania (appendix 2 p 83), whereas countries with the highest prevalence of smoking tobacco use among females were mostly in Europe and Oceania (appendix 2 p 84). Among the 159 countries with a population exceeding 1 million, the highest prevalence of smoking tobacco use in males aged 15 years and older was observed in Timor-Leste, Indonesia, Armenia, Jordan, and Georgia, and the highest prevalence of smoking tobacco use among females aged 15 years and older was observed in Serbia, Chile, Croatia, Bulgaria, and Greece (table). The ten countries with the largest number of tobacco smokers in 2019, together comprising nearly two-thirds of the global tobacco smoking population, were China, India, Indonesia, the USA, Russia, Bangladesh, Japan, Turkey, Vietnam, and the Philippines (appendix 2 pp 85–93); 341 million (30%) of 1.14 billion tobacco smokers globally lived in China in 2019.

Since 1990, global age-standardised prevalence of smoking tobacco use among males aged 15 years and older decreased by 27.5% (95% UI 26.5–28.5) and among females decreased by 37.7% (35.4–39.9), with variable progress across countries (table). Prevalence of smoking tobacco use among males aged 15 years and older decreased significantly between 1990 and 2019 in 135 countries (66%), but decreased significantly among females in only 68 countries (33%). The largest decreases were observed in Brazil, where prevalence decreased by 72.5% (70.1–74.7) among males and by 74.7% (71.2–78.0) among females. Among individuals aged 15 years and older, prevalence of smoking tobacco use decreased significantly between 1990 and 2019 in 122 countries (66%), but decreased significantly among females in only 59 countries (32%).

### Age-standardised prevalence, 2019

| Country                  | Females | Males | Percentage change, 1990–2019 |
|--------------------------|---------|-------|-----------------------------|
| Global                   | 6·62 (6·43 to 6·83) | 32·7 (32·3 to 33·0) | -37·7 (-39·9 to -35·4) |
| Central Europe, eastern Europe, and central Asia | 15·5 (14·9 to 16·2) | 39·5 (38·9 to 40·0) | -34·3 (-36·5 to -32·0) |
| Central Asia             | 3·79 (3·45 to 4·18) | 34·3 (33·5 to 35·1) | -5·97 (-19·7 to 7·78) |
| Armenia                  | 3·10 (2·48 to 3·79) | 55·5 (53·6 to 57·0) | -5·19 (-13·3 to 35·0) |
| Azerbaijan               | 2·50 (1·86 to 3·30) | 43·6 (41·9 to 45·2) | 30·8 (13·7 to 91·7) |
| Georgia                  | 7·02 (5·97 to 8·15) | 51·8 (50·0 to 53·6) | 11·3 (-16·7 to 45·2) |
| Kazakhstan               | 7·69 (6·46 to 9·16) | 43·2 (41·3 to 45·0) | 2.88 (-25·3 to 33·1) |
| Kyrgyzstan               | 4·65 (3·77 to 5·63) | 43·6 (41·7 to 45·5) | 49·0 (7·52 to 105) |
| Mongolia                 | 8·26 (6·86 to 9·84) | 51·7 (49·6 to 53·9) | 44·4 (7·67 to 88·9) |
| Tajikistan               | 1·29 (0·982 to 1·68) | 16·9 (15·7 to 18·3) | -41·7 (-61·7 to -15·0) |
| Turkmenistan             | 3·05 (2·34 to 3·93) | 21·6 (19·8 to 23·4) | -37·4 (-58·3 to -9·91) |
| Uzbekistan               | 1·94 (1·48 to 2·48) | 24·8 (23·1 to 26·6) | 47·9 (-0·335 to 117) |
| Central Europe           | 25·9 (25·0 to 26·7) | 35·8 (35·1 to 36·4) | -8·47 (-13·0 to -3·96) |
| Albania                  | 11·9 (9·87 to 14·2) | 51·5 (49·7 to 53·1) | 85·0 (30·1 to 145) |
| Bosnia and Herzegovina   | 30·5 (26·8 to 34·2) | 45·1 (42·6 to 47·5) | 41·1 (16·1 to 70·3) |
| Bulgaria                 | 32·5 (29·5 to 35·4) | 42·5 (40·4 to 44·6) | -16·2 (-29·5 to -0·400) |
| Croatia                  | 32·6 (29·9 to 35·5) | 39·1 (37·2 to 41·0) | -11·7 (-23·5 to 0·755) |
| Czech Republic           | 23·2 (21·3 to 25·2) | 34·1 (32·5 to 35·6) | -20·2 (-29·1 to -9·61) |
| Hungary                  | 26·5 (23·8 to 29·2) | 34·2 (32·0 to 36·1) | -18·4 (-29·4 to -6·22) |
| Montenegro               | 32·7 (30·3 to 35·2) | 37·5 (35·7 to 39·3) | 0·505 (-15·8 to 20·0) |
| North Macedonia          | 31·0 (28·3 to 33·9) | 47·1 (45·0 to 49·2) | 4·38 (-14·7 to 25·1) |
| Poland                   | 24·4 (22·5 to 26·3) | 31·8 (30·4 to 33·3) | -17·8 (-25·8 to -8·17) |
| Romania                  | 23·5 (21·7 to 25·5) | 38·4 (36·8 to 40·0) | -18·8 (-25·4 to -12·8) |
| Serbia                   | 37·8 (34·3 to 41·1) | 38·8 (36·9 to 40·8) | -20·3 (-25·9 to 38·9) |
| Slovakia                 | 20·9 (18·7 to 23·3) | 33·3 (31·2 to 35·3) | -14·9 (-31·4 to 4·94) |
| Slovenia                 | 24·9 (22·6 to 27·4) | 29·8 (28·0 to 31·5) | 9·05 (-11·3 to 30·7) |
| Eastern Europe           | 15·6 (14·4 to 17·0) | 44·7 (43·7 to 45·8) | 15·9 (2·24 to 31·3) |
| Belarus                  | 23·6 (20·7 to 26·6) | 50·2 (47·9 to 52·5) | 31·5 (0·570 to 69·1) |
| Latvia                   | 18·9 (17·2 to 20·7) | 31·7 (30·2 to 33·1) | -12·9 (-24·8 to -1·42) |
| Lithuania                | 21·3 (19·3 to 23·4) | 46·9 (45·2 to 48·7) | -3·33 (-18·8 to 15·5) |
| Moldova                  | 20·3 (18·4 to 22·6) | 37·3 (36·1 to 39·8) | 28·9 (10·4 to 50·4) |
| Russia                   | 15·5 (13·9 to 17·3) | 45·6 (44·1 to 47·0) | 26·1 (5·67 to 49·7) |
| Ukraine                  | 14·4 (12·7 to 16·3) | 42·0 (40·3 to 43·6) | -7·85 (-26·0 to 12·4) |

(Table continues on next page)
### Age-standardised prevalence, 2019

| Region                         | Females | Males | Percentage change 1990–2019 |
|-------------------------------|---------|-------|-----------------------------|
| **High income**               |         |       |                             |
| Australasia                   | 14·5 (12·7 to 16·5) | 16·7 (15·0 to 17·9) | -46·5 (-53·1 to -39·0) |
| Australia                     | 14·4 (12·2 to 16·7) | 16·4 (15·1 to 17·8) | -46·8 (-54·9 to -38·0) |
| New Zealand                   | 15·2 (13·9 to 16·5) | 18·4 (17·5 to 19·4) | -35·6 (-39·5 to -31·4) |
| High-income Asia Pacific      | 8·48 (7·49 to 9·64) | 35·9 (34·4 to 37·3) | -25·6 (-35·7 to -14·7) |
| Brunei                        | 5·39 (4·28 to 6·78) | 28·5 (26·1 to 31·2) | -31·3 (-50·9 to -7·75) |
| Japan                         | 10·2 (8·71 to 11·9) | 33·4 (31·4 to 35·5) | -23·6 (-35·2 to -9·65) |
| Singapore                     | 6·82 (5·38 to 8·41) | 20·6 (18·9 to 22·4) | -32·6 (-52·1 to -8·90) |
| South Korea                   | 5·21 (4·14 to 6·58) | 42·5 (40·1 to 44·7) | -18·4 (-42·8 to 11·5) |
| **High-income North America** |         |       |                             |
| Canada                        | 15·9 (13·4 to 18·6) | 18·3 (16·8 to 19·8) | -48·2 (-56·5 to -39·8) |
| Greenland                     | 42·3 (36·5 to 48·4) | 44·1 (40·9 to 47·3) | -5·3 (-21·0 to 13·6) |
| USA                           | 15·3 (13·9 to 16·7) | 19·9 (18·8 to 21·0) | -38·7 (-44·2 to -32·7) |
| Southern Latin America        | 23·3 (21·2 to 25·3) | 31·3 (29·9 to 32·7) | -20·0 (-31·2 to -8·02) |
| Argentina                     | 19·6 (17·3 to 22·2) | 29·2 (27·4 to 31·0) | -22·6 (-37·9 to -4·07) |
| Chile                         | 32·7 (28·7 to 36·6) | 36·2 (33·9 to 38·4) | -12·7 (-27·0 to 4·89) |
| Uruguay                       | 21·3 (19·4 to 26·3) | 31·0 (28·8 to 33·3) | -18·1 (-33·7 to -0·553) |
| Western Europe                | 22·7 (20·2 to 24·3) | 28·8 (26·2 to 30·3) | -24·2 (-26·7 to -21·8) |
| Andorra                       | 24·4 (19·6 to 29·5) | 31·4 (28·6 to 34·2) | -19·8 (-37·9 to 1·56) |
| Austria                       | 26·2 (23·4 to 29·0) | 36·1 (34·0 to 38·3) | -10·5 (-20·2 to 0·384) |
| Belgium                       | 21·4 (19·6 to 23·3) | 24·9 (23·6 to 26·2) | -28·5 (-35·6 to -21·1) |
| Cyprus                        | 21·3 (18·7 to 24·3) | 44·8 (42·6 to 47·1) | -11·6 (-30·8 to 9·57) |
| Denmark                       | 22·6 (20·6 to 24·8) | 22·7 (21·3 to 24·1) | -49·5 (-54·0 to -44·4) |
| Finland                       | 18·1 (16·3 to 20·3) | 24·8 (23·6 to 26·2) | -31·2 (-39·3 to -21·5) |
| France                        | 31·3 (28·8 to 33·9) | 36·9 (35·1 to 38·6) | -1·8 (-9·3 to 7·54) |
| Germany                       | 23·0 (21·1 to 24·9) | 29·9 (28·4 to 31·4) | -18·0 (-25·2 to -10·3) |
| Greece                        | 32·2 (29·5 to 35·1) | 44·1 (42·3 to 46·1) | -0·6 (-9·9 to 8·67) |
| Iceland                       | 15·1 (13·1 to 17·5) | 15·8 (14·7 to 17·1) | -47·7 (-56·6 to -37·8) |
| Ireland                       | 23·8 (20·4 to 25·3) | 21·9 (20·2 to 23·6) | -27·8 (-35·7 to -19·6) |
| Israel                        | 14·3 (12·8 to 17·2) | 26·4 (24·6 to 28·3) | -39·8 (-51·2 to -27·4) |
| Italy                         | 18·9 (17·3 to 20·6) | 27·3 (25·0 to 28·8) | -28·1 (-34·5 to -21·2) |
| Luxembourg                    | 21·3 (19·3 to 23·3) | 26·2 (24·5 to 28·0) | -27·9 (-36·3 to -19·1) |
| Malta                         | 22·0 (19·2 to 24·9) | 26·9 (24·8 to 28·8) | -15·0 (-30·9 to 2·21) |
| Monaco                        | 23·5 (18·9 to 28·6) | 29·0 (26·4 to 31·7) | -19·5 (-38·7 to 2·21) |
| Netherlands                   | 20·4 (18·6 to 22·2) | 25·0 (23·6 to 26·4) | -46·8 (-51·7 to -41·5) |
| Norway                        | 16·5 (14·3 to 18·9) | 20·2 (18·7 to 22·0) | -57·6 (-63·9 to -50·4) |
| Portugal                      | 22·4 (20·2 to 24·7) | 33·4 (31·7 to 35·9) | -30·6 (-36·3 to -24·5) |
| San Marino                    | 18·1 (15·2 to 21·5) | 21·6 (19·9 to 23·4) | -36·0 (-50·7 to -18·3) |
| Spain                         | 24·6 (22·6 to 26·8) | 30·7 (29·1 to 32·5) | -23·6 (-30·2 to -16·3) |
| Sweden                        | 14·6 (12·6 to 16·5) | 12·4 (11·1 to 13·5) | -47·1 (-54·5 to -38·7) |
| Switzerland                   | 23·4 (20·7 to 26·3) | 29·3 (27·2 to 31·2) | -18·9 (-28·6 to -8·35) |
| UK                            | 18·1 (16·3 to 19·9) | 21·7 (20·4 to 22·9) | -42·5 (-48·4 to -36·6) |
| Latin America and Caribbean   | 7·64 (7·16 to 8·10) | 17·1 (16·6 to 17·5) | -59·6 (-62·5 to -56·5) |
| Andean Latin America          | 4·84 (4·25 to 5·48) | 14·0 (13·3 to 14·6) | -17·4 (-33·4 to 0·994) |
| Bolivia                       | 7·31 (5·94 to 8·85) | 18·2 (16·8 to 19·7) | -9·3 (-32·9 to 16·6) |
| Ecuador                       | 4·97 (4·14 to 5·98) | 24·7 (23·5 to 25·9) | -18·1 (-38·7 to 7·54) |
| Peru                          | 4·02 (3·22 to 4·95) | 7·33 (6·56 to 8·20) | -23·2 (-47·1 to 9·24) |

*(Table continues on next page)*
| Country                      | Age-standardised prevalence, 2019 | Percentage change 1990–2019 |
|------------------------------|----------------------------------|-----------------------------|
|                              | Females | Males            | Females | Males            |
| Caribbean                    |         |                  |         |                  |
| Antigua and Barbuda          | 5·58     | 8·65 (7·76 to 9·55) | 19·6     | 19·8 (18·9 to 20·4) |
| The Bahamas                  | 3·18     | 11·4 (10·4 to 12·6) | -11·4    | -11·4 (–38·4 to 27·1) |
| Barbados                     | 4·61     | 13·9 (12·6 to 15·5) | -3·25    | -3·25 (–34·2 to 38·0) |
| Belize                       | 4·13     | 22·7 (20·4 to 24·6) | 9·24     | 9·24 (–25·9 to 50·3) |
| Bermuda                      | 8·32     | 18·1 (16·5 to 19·9) | -2·45    | -2·45 (–28·8 to 33·4) |
| Cuba                         | 15·3     | 31·8 (29·4 to 34·4) | -34·2    | -34·2 (–49·2 to 15·1) |
| Dominican Republic           | 9·27     | 13·7 (12·6 to 14·9) | -21·0    | -21·0 (–29·6 to 1·13) |
| Grenada                      | 5·39     | 17·7 (15·8 to 19·6) | 2·57     | 2·57 (–30·5 to 44·3) |
| Guyana                       | 4·20     | 24·9 (23·2 to 26·8) | -9·62    | -9·62 (–26·7 to 22·6) |
| Haiti                        | 2·65     | 10·1 (9·22 to 11·0) | -48·6    | -48·6 (–65·2 to 27·5) |
| Jamaica                      | 6·82     | 20·1 (18·5 to 21·6) | -21·8    | -21·8 (–40·1 to 0·23) |
| Puerto Rico                  | 8·57     | 16·0 (14·9 to 17·2) | -14·2    | -14·2 (–31·8 to 6·44) |
| Saint Kitts and Nevis        | 2·87     | 10·5 (9·30 to 11·8) | -0·0613  | -0·0613 (–32·4 to 41·3) |
| Saint Lucia                  | 5·27     | 19·2 (17·4 to 21·1) | -14·2    | -14·2 (–39·3 to 18·3) |
| Saint Vincent and the Grenadines | 4·24     | 20·3 (18·5 to 22·1) | 2·04     | 2·04 (–28·9 to 41·4) |
| Suriname                     | 8·85     | 34·2 (31·7 to 36·6) | -25·5    | -25·5 (–46·9 to 0·950) |
| Trinidad and Tobago          | 8·17     | 28·9 (26·6 to 31·2) | -7·88    | -7·88 (–34·0 to 26·3) |
| Virgin Islands               | 4·98     | 8·28 (7·38 to 9·22) | -24·3    | -24·3 (–46·3 to 2·89) |
| Central Latin America        | 8·72     | 22·7 (20·2 to 23·4) | -42·2    | -42·2 (–49·0 to 34·4) |
| Colombia                     | 9·71     | 14·7 (13·6 to 15·9) | -33·3    | -33·3 (–49·3 to 13·6) |
| Costa Rica                   | 7·19     | 15·3 (14·1 to 16·6) | -48·2    | -48·2 (–60·7 to 32·1) |
| El Salvador                  | 3·70     | 17·3 (15·8 to 18·9) | 36·9     | 36·9 (5·05 to 87·8) |
| Guatemala                    | 4·34     | 20·5 (19·0 to 22·0) | -5·00    | -5·00 (–32·1 to 29·7) |
| Honduras                     | 5·25     | 24·0 (22·2 to 25·9) | -11·8    | -11·8 (–35·3 to 16·4) |
| Mexico                       | 9·01     | 27·5 (25·7 to 28·2) | -48·1    | -48·1 (–57·1 to 38·3) |
| Nicaragua                    | 5·46     | 21·5 (19·5 to 23·7) | -16·2    | -16·2 (–42·4 to 17·4) |
| Panama                       | 4·57     | 12·4 (11·3 to 13·7) | -35·9    | -35·9 (–54·5 to 10·6) |
| Venezuela                    | 11·7     | 22·8 (20·5 to 25·2) | -32·2    | -32·2 (–49·8 to 11·0) |
| Tropical Latin America       | 6·90     | 11·2 (10·0 to 11·9) | -73·4    | -73·4 (–77·3 to 70·8) |
| Brazil                       | 6·86     | 10·9 (10·1 to 11·6) | -74·7    | -74·7 (–78·0 to 71·2) |
| Paraguay                     | 8·33     | 24·6 (22·7 to 26·7) | -41·9    | -41·9 (–56·4 to 24·7) |
| North Africa and Middle East | 5·63     | 32·4 (31·9 to 32·9) | -2·88    | -2·88 (–12·7 to 7·23) |
| Afghanistan                  | 2·67     | 17·0 (15·7 to 18·4) | 179·03   | 179·03 (4·0 to 285) |
| Algeria                      | 1·74     | 32·7 (30·6 to 34·8) | -28·7    | -28·7 (–51·5 to 0·699) |
| Bahrain                      | 5·10     | 23·4 (21·4 to 25·5) | -20·7    | -20·7 (–40·4 to 2·68) |
| Egypt                        | 1·06     | 43·4 (42·2 to 44·7) | 2·41     | 2·41 (–31·7 to 50·5) |
| Iran                         | 4·73     | 24·9 (23·2 to 26·5) | 8·28     | 8·28 (–26·7 to 47·9) |
| Iraq                         | 3·53     | 37·6 (35·4 to 39·6) | -22·1    | -22·1 (–45·0 to 5·61) |
| Jordan                       | 11·8     | 53·0 (51·5 to 54·5) | 10·6     | 10·6 (–15·8 to 64·6) |
| Kuwait                       | 4·72     | 33·5 (31·5 to 35·8) | -8·57    | -8·57 (–36·3 to 24·3) |
| Lebanon                      | 26·0     | 46·1 (44·0 to 48·2) | 45·1     | 45·1 (15·8 to 80·2) |
| Libya                        | 1·46     | 38·6 (36·3 to 41·0) | -2·10    | -2·10 (–34·2 to 0·84) |
| Morocco                      | 1·06     | 22·5 (20·9 to 24·1) | -31·3    | -31·3 (–54·3 to 1·02) |
| Oman                         | 1·88     | 15·8 (14·5 to 17·3) | -1·10    | -1·10 (–37·4 to 23·1) |
| Palestine                    | 3·89     | 40·8 (38·6 to 43·2) | -3·23    | -3·23 (–29·4 to 28·9) |
| Qatar                        | 2·97     | 21·3 (20·3 to 23·6) | 4·14     | 4·14 (–32·9 to 54·7) |
| Saudi Arabia                 | 2·17     | 22·6 (21·1 to 24·0) | 45·3     | 45·3 (0·241 to 99·6) |

(Table continues on next page)
### Age-standardised prevalence, 2019

| Country | Females | Males | Percentage change 1990–2019 |
|---------|---------|-------|-----------------------------|
| Sudan   | 1·95 (1·46 to 2·54) | 19·5 (18·0 to 21·1) | -15·2 (-42·5 to 23·4) |
| Syria   | 6·20 (4·77 to 7·97)  | 41·9 (39·0 to 44·8)  | -23·3 (-47·1 to 6·07) |
| Tunisia | 2·70 (2·12 to 3·45)  | 45·4 (43·2 to 47·7)  | -19·9 (-43·5 to 10·8) |
| Turkey  | 18·4 (16·5 to 20·3)  | 43·8 (41·4 to 46·4)  | 14·6 (3·8 to 33·5) |
| United Arab Emirates | 3·79 (2·96 to 4·81) | 17·9 (16·2 to 19·3) | 2·58 (-27·0 to 44·1) |
| Yemen   | 8·90 (7·46 to 10·7)  | 31·5 (29·5 to 33·6)  | 4·41 (-24·0 to 40·2) |
| South Asia | 3·26 (2·83 to 3·78) | 25·2 (24·2 to 26·2) | -34·1 (-45·8 to -21·1) |
| Bangladesh | 2·13 (1·68 to 2·66) | 44·9 (43·0 to 47·0) | -27·9 (-47·7 to -4·36) |
| Bhutan  | 4·80 (3·79 to 5·95)  | 14·8 (13·4 to 16·2)  | -6·2 (-33·8 to 31·6) |
| India   | 3·10 (2·59 to 3·74)  | 23·0 (21·5 to 24·2)  | -1·2 (-23·6 to 12·9) |
| Nepal   | 13·6 (11·9 to 15·6)  | 24·7 (23·3 to 25·9)  | -7·7 (-41·9 to 36·6) |
| Europe  | 3·94 (3·51 to 4·39)  | 49·4 (48·4 to 50·4)  | -22·1 (-33·2 to -11·0) |
| East Asia | 3·57 (2·97 to 4·18) | 49·5 (48·0 to 50·8) | -20·7 (-36·4 to -3·84) |
| China   | 3·54 (2·91 to 4·38)  | 49·7 (48·3 to 52·1)  | -20·9 (-37·4 to -3·53) |
| North Korea | 4·48 (3·57 to 5·69) | 11·6 (10·7 to 12·7) | -1·4 (-15·3 to 9·8) |
| Taiwan (Province of China) | 4·98 (3·94 to 6·21) | 39·6 (37·5 to 42·1) | -27·9 (-51·0 to -0·968) |
| Oceania | 18·0 (16·2 to 20·2)  | 41·3 (39·4 to 43·2)  | -17·7 (-32·1 to -1·23) |
| American Samoa | 22·4 (18·3 to 27·2) | 41·1 (39·2 to 43·2) | -17·7 (-32·1 to -1·23) |
| Cook Islands | 24·0 (20·5 to 28·6) | 36·7 (34·3 to 39·1) | -7·7 (-21·8 to 35·9) |
| Federated States of Micronesia | 36·4 (31·0 to 41·5) | 62·2 (59·3 to 64·8) | 12·4 (-9·5 to 35·5) |
| Fiji | 14·5 (12·0 to 17·3)  | 42·5 (40·0 to 45·4)  | -18·9 (-38·4 to 6·27) |
| Guam    | 20·1 (17·8 to 22·3)  | 30·3 (28·6 to 32·1)  | -8·2 (-26·4 to 12·2) |
| Kiribati | 35·1 (31·5 to 38·6)  | 63·8 (61·0 to 65·9)  | 6·8 (1·6 to 21·3) |
| Marshall Islands | 9·75 (7·74 to 12·0) | 30·5 (27·1 to 34·7) | 21·1 (-9·19 to 75·7) |
| Nauru   | 40·3 (36·3 to 44·6)  | 43·3 (40·7 to 46·8)  | -7·1 (-21·2 to 8·9) |
| Niue    | 15·8 (13·1 to 18·8)  | 20·7 (17·7 to 24·0)  | -3·1 (-26·2 to 3·2) |
| Northern Mariana Islands | 18·0 (14·3 to 22·1) | 41·0 (38·0 to 43·9) | -7·6 (-37·6 to 8·2) |
| Palau   | 12·6 (10·9 to 15·4)  | 30·6 (26·0 to 34·3)  | -8·8 (-25·5 to 25·2) |
| Papua New Guinea | 18·4 (15·8 to 21·3) | 40·2 (37·7 to 42·6) | -21·2 (-37·8 to 8·8) |
| Samoa   | 14·5 (12·0 to 17·6)  | 39·7 (34·2 to 41·6)  | -11·6 (-32·5 to 3·8) |
| Solomon Islands | 19·3 (17·0 to 21·8) | 52·2 (49·3 to 54·2) | 7·0 (16·4 to 36·0) |
| Tokelau | 16·4 (13·6 to 20·6)  | 39·6 (36·6 to 42·5)  | 0·1 (16·1 to 21·3) |
| Tonga   | 13·3 (11·3 to 15·4)  | 42·5 (39·0 to 44·8)  | -2·9 (-20·6 to 23·1) |
| Tuvalu  | 20·7 (17·3 to 24·4)  | 45·4 (42·6 to 48·0)  | 7·2 (-27·7 to 42·3) |
| Vanuatu | 5·70 (4·54 to 6·95)  | 38·2 (36·0 to 40·3)  | -7·8 (-43·4 to 14·2) |
| Southeast Asia | 4·51 (4·18 to 4·87) | 48·2 (42·7 to 47·8) | -9·9 (-37·0 to 0·0) |
| Cambodia | 5·09 (4·17 to 6·10) | 46·0 (38·3 to 42·7) | -13·9 (-34·6 to 10·6) |
| Indonesia | 3·60 (3·00 to 4·33) | 58·3 (53·7 to 59·8) | 7·9 (17·2 to 39·2) |
| Laos    | 6·98 (5·73 to 8·29)  | 49·1 (46·8 to 52·1)  | 29·3 (6·7 to 71·2) |
| Malaysia | 3·20 (2·57 to 3·93)  | 40·3 (37·5 to 43·8)  | -26·0 (-47·5 to 7·0) |
| Maldives | 7·35 (5·85 to 9·03)  | 46·5 (44·8 to 48·9)  | -9·8 (-32·8 to 23·8) |
| Mauritius | 5·40 (3·66 to 7·51) | 41·2 (39·2 to 43·3) | -7·6 (-32·1 to 23·3) |
| Myanmar | 8·59 (7·24 to 10·0) | 41·0 (37·8 to 42·5) | -8·7 (-59·6 to 35·3) |
| Philippines | 8·24 (7·24 to 9·51) | 42·0 (39·4 to 43·5) | -3·7 (-50·7 to 29·6) |
| Seychelles | 7·01 (5·58 to 8·62) | 39·7 (36·3 to 42·4) | -5·3 (-34·0 to 30·1) |
| Sri Lanka | 1·80 (1·39 to 2·26) | 30·1 (28·5 to 31·8) | -4·0 (-58·4 to -17·4) |

(Table continues on next page)
| Country                        | 2019 | Percentage change 1990–2019 |
|-------------------------------|------|-----------------------------|
| Thailand                      | 3.49 (2.39 to 4.19) | -46.5 (-59.9 to -31.5) |
| Timor-Leste                   | 5.15 (4.18 to 6.21)  | -4.15 (-30.1 to 26.9)  |
| Vietnam                       | 2.68 (2.13 to 3.30)  | -32.9 (-50.2 to -13.4) |
| Sub-Saharan Africa            | 2.94 (2.78 to 3.10)  | -34.1 (-39.1 to -28.9) |
| Central sub-Saharan Africa    | 1.74 (1.46 to 2.06)  | -4.72 (-26.1 to 18.9)  |
| Angola                        | 2.74 (2.14 to 3.51)  | -9.87 (-36.6 to 23.5)  |
| Central African Republic      | 1.60 (1.22 to 2.12)  | -26.1 (-50.2 to 4.37)  |
| Congo (Brazzaville)           | 1.81 (1.33 to 2.42)  | 20.3 (-24.1 to 75.6)   |
| Democratic Republic of the Congo | 1.36 (1.01 to 1.79)  | -6.49 (-38.2 to 34.9)  |
| Equatorial Guinea             | 2.50 (1.81 to 3.47)  | 4.27 (-36.2 to 52.8)   |
| Gabon                         | 3.55 (2.71 to 4.54)  | 26.1 (-17.1 to 84.3)   |
| Eastern sub-Saharan Africa    | 3.14 (2.93 to 3.37)  | -18.6 (-26.5 to -6.9)  |
| Burundi                       | 4.23 (3.38 to 5.28)  | -31.9 (-52.9 to 24.8)  |
| Comoros                       | 2.99 (2.31 to 3.76)  | -6.26 (-35.1 to 35.3)  |
| Djibouti                      | 5.52 (4.36 to 6.90)  | 14.4 (-48.8 to 61.3)   |
| Eritrea                       | 0.696 (0.517 to 0.906)| -20.8 (-48.8 to 13.5) |
| Ethiopia                      | 1.21 (1.01 to 1.69)  | -3.20 (-33.3 to 33.7)  |
| Kenya                         | 2.52 (2.00 to 3.20)  | -35.2 (-54.4 to -9.9)  |
| Madagascar                    | 2.57 (2.00 to 3.30)  | -40.1 (-57.7 to -16.5) |
| Malawi                        | 3.11 (2.44 to 3.93)  | -15.5 (-41.7 to 17.8)  |
| Mozambique                    | 5.94 (4.68 to 7.39)  | -7.30 (-34.1 to 27.9)  |
| Rwanda                        | 5.83 (5.00 to 10.1)  | -1.82 (-26.9 to 29.3)  |
| Somalia                       | 2.82 (2.17 to 3.66)  | -17.9 (-43.1 to 12.0)  |
| South Sudan                   | 2.71 (2.05 to 3.43)  | -18.4 (-42.3 to 9.3)   |
| Uganda                        | 4.18 (3.43 to 5.02)  | -1.00 (-26.2 to 31.2)  |
| Tanzania                      | 2.96 (2.35 to 3.68)  | -27.7 (-49.0 to 1.96)  |
| Zambia                        | 5.82 (4.75 to 6.99)  | -10.0 (-32.5 to 18.6)  |
| Southern sub-Saharan Africa   | 8.70 (7.51 to 10.0)  | -36.8 (-47.8 to -25.7) |
| Botswana                      | 8.39 (7.02 to 9.77)  | -91.9 (-38.0 to 7.26)  |
| eSwatini                      | 2.87 (2.28 to 3.67)  | -26.9 (-47.4 to -17.1) |
| Lesotho                       | 1.85 (1.42 to 2.42)  | -4.41 (-27.9 to 50.9)  |
| Namibia                       | 10.6 (8.81 to 12.7)  | -25.7 (-43.6 to -5.0)  |
| South Africa                  | 10.4 (8.75 to 12.0)  | -38.0 (-50.2 to -24.8) |
| Zimbabwe                      | 3.47 (2.73 to 4.29)  | -8.90 (-35.9 to 24.1)  |
| Western sub-Saharan Africa    | 1.81 (1.64 to 2.02)  | -33.7 (-42.9 to -23.4) |
| Benin                         | 1.69 (1.28 to 2.15)  | -45.1 (-63.0 to -23.6) |
| Burkina Faso                  | 1.47 (1.03 to 2.03)  | -32.4 (-55.5 to -9.1)  |
| Cameroon                      | 1.51 (1.14 to 1.94)  | -24.1 (-47.2 to -6.2)  |
| Cape Verde                    | 3.00 (2.36 to 3.83)  | -25.2 (-54.4 to -9.6)  |
| Chad                          | 2.83 (2.23 to 3.63)  | -33.7 (-54.0 to -7.6)  |
| Côte d’Ivoire                 | 3.79 (2.89 to 4.83)  | -33.7 (-42.9 to -23.9) |
| The Gambia                    | 1.33 (1.02 to 1.72)  | -35.0 (-55.2 to -9.3)  |
| Ghana                         | 2.08 (1.58 to 2.72)  | 6.37 (-26.7 to 56.4)   |
| Guinea                        | 2.02 (1.54 to 2.56)  | -6.65 (-34.9 to 30.3)  |
| Guinea-Bissau                 | 1.07 (0.811 to 1.39)| 3.39 (-29.1 to 46.7)  |
| Liberia                       | 2.57 (2.03 to 3.24)  | 1.62 (-30.8 to 43.3)   |
| Mali                          | 2.44 (1.83 to 3.22)  | 4.76 (-2.93 to 11.3)   |
| Mauritania                    | 8.08 (6.28 to 10.1)  | -12.3 (-39.3 to 20.6)  |
| Niger                         | 1.63 (1.23 to 2.16)  | 18.3 (-21.9 to 68.9)   |

(Table continues on next page)
increased significantly over the past 30 years in 20 countries for males (Afghanistan, Saudi Arabia, Uzbekistan, El Salvador, Antigua and Barbuda, Lesotho, Congo [Brazzaville], Mali, Albania, Lebanon, São Tomé and Príncipe, Bosnia and Herzegovina, Gabon, Djibouti, Egypt, Jordan, Mongolia, Laos, Kiribati, and Indonesia) and in 12 countries for females (Afghanistan, Albania, Kyrgyzstan, Saudi Arabia, Lebanon, Mongolia, Bosnia and Herzegovina, Belarus, Portugal, Lithuania, Russia, and Serbia; table). Across both sexes combined, the largest decreases in age-standardised prevalence of smoking tobacco use were observed in Brazil (73.4% [71.4–75.2]), Norway (53.5% [49.1–57.6]), Senegal (50.9% [44.6–56.0]), Iceland (49.7% [44.5–54.1]), Denmark (49.3% [46.4–52.2]), Haiti (47.5% [40.5–54.4]), Australia (47.5% [43.1–51.8]), Costa Rica (47.4% [40.5–53.6]), Canada (47.4% [42.4–52.0]), and Colombia (47.1% [40.4–53.4]; appendix 2 pp 94–102).

Analysing the annualised rate of change per 5-year period in individuals aged 15 years and older between 1990 and 2019, we found the largest number of countries had their fastest decrease in age-standardised prevalence of smoking tobacco use between 2005 and 2009 for both males (68 countries) and females (56 countries; figure 1; country-level data are available online through the GHDx). Overall, 115 (56%) of 204 countries for males and 136 (67%) countries for females had their fastest decrease after the FCTC was ratified (ie, after 2005). Notably, decreases in prevalence were smaller in the period 2015–19 than in the period 2010–15 in

### Table: Age-standardised prevalence of current smoking tobacco use in 1990–2019 among individuals aged 15 years and older, by location and sex

| Location                  | Age-standardised prevalence, 2019 | Percentage change 1990–2019 |
|---------------------------|----------------------------------|-----------------------------|
|                           | Females                          | Males                       | Females                          | Males                       |
| Nigeria                   | 1.16 (0.862 to 1.54)             | 7.43 (6.69 to 8.21)         | -53.3 (-67.9 to -33.2)           | -38.5 (-46.7 to -30.1)     |
| São Tomé and Principe     | 1.70 (1.29 to 2.22)              | 7.80 (6.95 to 8.69)         | 15.1 (-23.8 to 70.5)            | 24.2 (5.43 to 43.3)        |
| Senegal                   | 1.46 (1.11 to 1.90)              | 14.2 (12.3 to 15.3)         | -41.2 (-60.4 to -17.5)          | -52.3 (-57.5 to -46.0)     |
| Sierra Leone              | 7.84 (6.34 to 9.61)              | 30.5 (28.7 to 32.6)         | -26.1 (-46.8 to 0.307)          | -13.1 (-21.4 to -3.07)    |
| Togo                      | 2.26 (1.73 to 2.92)              | 14.0 (12.8 to 15.2)         | -37.3 (-57.5 to -11.9)          | -42.8 (-49.8 to -35.5)    |

Data are given to three significant figures. Data in parentheses are 95% uncertainty intervals.

For country-level data see http://ghdx.healthdata.org/record/ihme-data/gbd-2019-smoking-tobacco-use-prevalence-1990-2019
152 (75%) countries for males and 137 (67%) countries for females (figure 1; country-level data are available online through the GHDx).

In many countries, reductions in prevalence have not kept pace with population growth (figure 1; appendix 2 pp 94–102). As a result, the number of smokers globally has increased steadily each year since 1990, when there were 0·99 billion (95% UI 0·98–1·00) smokers globally, with the exception of the period between 2011 and 2017, during which no significant change in the number of smokers occurred (figure 1). Of 204 countries and territories included in our analysis, 113 (55%) had a significant increase in the number of current smokers between 1990 and 2019 and 111 (54%) had a significant increase between 2005 and 2019. Among both males and females, the super-regions with the largest relative increases in the number of smokers since 1990 were north Africa and the Middle East (104·1% [98·1–111] increase) and sub-Saharan Africa (74·6% [69·9–79·1] increase; appendix 2 pp 94–102). The largest relative decreases in the number of smokers were observed in the Latin America and the Caribbean (19·8% [16·9–22·5] decrease) and high-income (17·6% [16·2–18·9] decrease) super-regions.

7·41 trillion (95% UI 7·11–7·74) cigarette-equivalents of tobacco were consumed in 2019, amounting to 20·3 billion (19·5–21·2) cigarette-equivalents consumed each day worldwide. China accounted for more than a third of the world’s tobacco consumption (2·72 trillion [2·47–3·01] cigarette-equivalents). Countries with the highest consumption per person in 2019 were mostly in Europe, with Montenegro, North Macedonia, Bulgaria, Slovenia, and Greece all having consumption exceeding 2350 cigarette-equivalents per person (appendix 2 pp 103–111). Countries with the lowest consumption per person were mostly in sub-Saharan Africa (appendix 2 pp 103–110).

Cigarettes smoked per day is an important predictor of disease risk, although smokers who consume only a few cigarettes each day still have considerable excess risk compared with non-smokers. Among 719 million male current smokers aged 30 years and older in 2019, 83·2 million (11·6%) smoked 1–4 cigarette-equivalents per day, 139·2 million (19·4%) smoked 5–9 cigarette-equivalents per day, 144·0 million (20·0%) smoked 10–14 cigarette-equivalents per day, 120·5 million (16·8%) smoked 15–19 cigarette-equivalents per day, and 231·9 million (32·3%) smoked 20 or more cigarette-equivalents per day (figure 2). Among 146 million female current smokers aged 30 years and older in 2019, 27·0 million (18·5%) smoked 1–4 cigarette-equivalents per day, 39·0 million (26·7%) smoked 5–9 cigarette-equivalents per day, 32·4 million (22·1%) smoked 10–14 cigarette-equivalents per day, 20·8 million (14·2%) smoked 15–19 cigarette-equivalents per day, and 27·1 million (18·5%) smoked 20 or more cigarette-equivalents per day (figure 2). The distribution of cigarette-equivalents per smoker per day varies across countries. Most of the male current smoker population aged 30 years and older in 72 countries and most of the female current smoker population in 121 countries smoke fewer than 10 cigarette-equivalents per day on average (data not shown).

In 2019, 7·69 million (95% UI 7·16–8·20) deaths and 200 million (185–214) DALYs were attributable to

![Figure 2: Distribution of number of tobacco smokers aged 30 years and older, by cigarette-equivalents smoked per day (A), and pack-years among current smokers (B), and years since quitting among former smokers (C), by sex and geographical region in 2019](https://example.com/figure2.jpg)
smoking tobacco use, accounting for 13·6% (13·0–14·3) of all deaths and 7·89% (7·19–8·56) of all DALYs (appendix 2 pp 112–165). 6·18 million (80%) of these deaths were among males, and smoking accounted for the largest number and proportion (20·2% [19·3–21·1]) of deaths among males of the 87 risk factors included in GBD 2019.1 Among females, smoking accounted for 1·51 million (1·40–1·63) deaths and 5·84% (5·47–6·22) of all deaths. YLLs due to smoking tobacco use, which quantify the effects of premature mortality, exceeded YLDs due to smoking in 2019, which quantify the effects of non-fatal health loss. (168 million [156–180] YLLs vs 31·6 million [23·7–40·0] YLDs). The ratio of YLLs to YLDs attributable to smoking tobacco use varied across countries, from 1·59 (1·03–2·44) in Qatar to 16·1 (11·2–22·7) in the Solomon Islands (appendix 2 pp 166–174). Ratios of YLLs to YLDs decreased with increasing Socio-demographic Index level (appendix 2 p 175). Lower ratios of YLLs to YLDs indicate that a greater proportion of individuals are living with chronic health conditions due to smoking tobacco use in these countries than in countries with higher ratios of YLLs to YLDs.

Of the 36 health outcomes caused by smoking tobacco use (appendix 2 pp 5–82), the health outcomes with the largest number of deaths attributable to smoking tobacco use for both sexes combined in 2019 were ischaemic heart disease (1·68 million [95% UI 1·56–1·81]); chronic obstructive pulmonary disease (1·59 million [1·41–1·76]); tracheal, bronchus, and lung cancer (1·31 million [1·20–1·43]); and stroke (0·931 million [0·833–1·00]; appendix 2 pp 176–177), which together accounted for approximately 72% of all deaths attributable to smoking tobacco use that year. Top causes of death attributable to smoking varied by region, reflecting differences in both background cause-specific death rates and patterns of smoking. Ischaemic heart disease was the leading cause of deaths attributable to smoking tobacco use in all super-regions except the high-income super-region, for which the leading cause was lung cancer, and for countries in the southeast Asia, east Asia, and Oceania super-region for which the leading cause was chronic obstructive pulmonary disease (appendix 2 pp 176–177).

An estimated 5·96 million (77·5%) of 7·69 million deaths attributable to smoking tobacco use in 2019 were ischaemic heart disease (1·68 million [95% UI 1·56–1·81]); chronic obstructive pulmonary disease (1·59 million [1·41–1·76]); tracheal, bronchus, and lung cancer (1·31 million [1·20–1·43]); and stroke (0·931 million [0·833–1·00]; appendix 2 pp 176–177), which together accounted for approximately 72% of all deaths attributable to smoking tobacco use that year. Top causes of death attributable to smoking varied by region, reflecting differences in both background cause-specific death rates and patterns of smoking. Ischaemic heart disease was the leading cause of deaths attributable to smoking tobacco use in all super-regions except the high-income super-region, for which the leading cause was lung cancer, and for countries in the southeast Asia, east Asia, and Oceania super-region for which the leading cause was chronic obstructive pulmonary disease (appendix 2 pp 176–177).

An estimated 5·96 million (77·5%) of 7·69 million deaths attributable to smoking tobacco use in 2019 were ischaemic heart disease (1·68 million [95% UI 1·56–1·81]); chronic obstructive pulmonary disease (1·59 million [1·41–1·76]); tracheal, bronchus, and lung cancer (1·31 million [1·20–1·43]); and stroke (0·931 million [0·833–1·00]; appendix 2 pp 176–177), which together accounted for approximately 72% of all deaths attributable to smoking tobacco use that year. Top causes of death attributable to smoking varied by region, reflecting differences in both background cause-specific death rates and patterns of smoking. Ischaemic heart disease was the leading cause of deaths attributable to smoking tobacco use in all super-regions except the high-income super-region, for which the leading cause was lung cancer, and for countries in the southeast Asia, east Asia, and Oceania super-region for which the leading cause was chronic obstructive pulmonary disease (appendix 2 pp 176–177).

Across all age groups, smoking tobacco use was the cause of more than 20% of all male deaths in 73 countries in 2019 (figure 3). 43 (59%) of 73 countries were designated as low-income or middle-income countries. Among all females, smoking accounted for more than 20% of deaths in only two locations (Denmark and Greenland), due to both lower smoking prevalence, shorter duration of smoking, and lower smoking intensity among females than among males (figure 3). The proportion of deaths attributable to smoking tobacco use increased with age, peaking among those aged 60–64 years (22·0% [95% UI 21·1–23·1] of deaths attributable to smoking), before decreasing in older age groups (appendix 2 p 178).

The share of all-cause deaths that were due to smoking tobacco use decreased significantly between 1990 and 2019 in 68 countries, increased significantly in 71 countries, and stayed constant in 65 countries (appendix 2 pp 179–187). 66 (93%) of 71 countries with significant increases in the proportion of all-cause deaths attributable to smoking tobacco use were low-income and middle-income countries. The largest decreases were observed in Australia, New Zealand, South Africa, Singapore, and Norway, whereas the largest increases were observed in Timor-Leste, Bhutan, Niger, São Tomé and Príncipe, and Malawi (appendix 2 pp 179–187). The largest absolute increases in the number of deaths attributable to tobacco smoking between 1990 and 2019 were observed in China (from 1·5 million deaths in 1990 to 2·4 million in 2019; a 57·9% [26·2–101] increase), India (from 0·6 million deaths in 1990 to 1·0 million in 2019; a 58·9% [30·7–90·8] increase), and Indonesia (from 112,800 deaths in 1990 to 246,400 deaths in 2019; a 118% [74·0–171] increase; appendix 2 pp 179–187).

The dose-response association between risk exposure and disease results in an uneven distribution of burden among the current and former smoking populations aged 30 years and older (figure 4). Among ever smokers aged 30 years and older, 865 million (65·9%) of 1·31 billion are current smokers and 449 million (34·1%) are former smokers. A disproportionate share of all deaths attributable to smoking tobacco use occurred among current smokers (6·68 million [86·9%] of 7·69 million). Among former smokers, health risks decreased as a function of years since cessation (figure 4). Only 0·467 million (6·18%) global deaths attributable to smoking tobacco use occurred among individuals who had quit smoking at least 15 years ago, despite this group accounting for 257 million (19·6%) members of the global ever smoker population.

Discussion
In this study, we present updated results on the prevalence of smoking tobacco use and the attributable disease burden from GBD 2019. We used new direct estimation methods, which allowed more comprehensive estimations, including reflecting dose-response associations between exposure and risk of disease and capture of health effects among daily and occasional smokers and former smokers. By using continuous
Figure 3: Proportion of all-cause deaths that were attributable to smoking tobacco use among females (A) and males (B) of all ages in 2019.
In 2019, more than 1 billion people smoked tobacco regularly, and almost 8 million deaths were attributable to smoking. Smoking tobacco use accounted for 20.2% of all-cause deaths among males, and was the leading risk factor for both deaths and DALYs among males. Among females, smoking tobacco use accounted for approximately 5.8% of all deaths, due to lower prevalence, shorter duration, and lower intensity of smoking than in males. Tobacco control has contributed to reductions in global prevalence of smoking tobacco use of 27.5% (95% UI 26.5–28.5) for males and 37.7% (35.4–39.9) for females. However, these global aggregates do not illustrate important between-country heterogeneity. Between 1990 and 2019, significant decreases in prevalence of smoking tobacco use were observed in 135 countries for males and 68 countries for females, while significant increases were observed in 20 countries for males and 12 countries for females.

Although tobacco control efforts began as early as in the 1960s in some countries after the detrimental health effects of tobacco smoking were first documented, global progress in tobacco control was catalysed with the passing of the WHO FCTC in 2005. The decade following the introduction of the WHO FCTC was the period of fastest decrease in the prevalence of smoking tobacco use across the largest number of countries. The effectiveness of the demand-reduction policies outlined in the FCTC articles has been documented, and the large reductions in prevalence of smoking tobacco use between 1990 and 2019 were observed in Brazil (73.4% decrease), Norway (53.5% decrease), and Senegal (50.9% decrease), along with Iceland, Denmark, Canada, Australia, Colombia, and Costa Rica, all with decreases in prevalence exceeding 45%, show the potential of these tools to operate in diverse contexts to greatly reduce the prevalence of smoking tobacco use and save millions of lives over the coming decades.

Despite these successes, we observed three concerning patterns. First, in several countries with large populations and high prevalence of smoking tobacco use, including China (2.4 million deaths in 2019, a 57.9% [95% UI 26.2–101] increase in attributable deaths since 1990) and Indonesia (246,400 deaths in 2019, a 118% [74.0–171] increase in attributable deaths since 1990), little to no progress has been made in reducing the prevalence of smoking. Second, most countries did not have sufficient decreases in the prevalence of smoking to offset the demographic force of population growth, resulting in constant or increasing numbers of smokers over time. And third, in many countries, including those that had large decreases in prevalence previously, the rate of progress has slowed, particularly in the past 5 years.

113 of 204 countries had a significant increase in the number of smokers since 1990, and 111 countries had a significant increase since 2005. To achieve the goals set forth in the SDGs and WHO global non-communicable disease monitoring framework, and in doing so reclaim the 200 million DALYs lost to smoking tobacco use each year, most countries will need exposure measures, we are better able to capture differences in risk across countries that result from heterogenous smoking patterns. Our findings are an urgent call to action for countries to implement and enforce stronger tobacco control policies than are currently in place, and serve as a blueprint for targeting interventions, monitoring progress, allocating resources, and planning for future health system strain.

In 2019, more than 1 billion people smoked tobacco regularly, and almost 8 million deaths were attributable...
stronger tobacco control policies than those already in place. As of 2018, only 62 countries had comprehensive smoke-free policies; 23 offered the full range of cessation support services recommended by WHO; 91 mandated best-practice pictorial health warnings; 48 were protected by complete advertising, promotion, and sponsorship bans; and 38 had the recommended level of tobacco taxation. Closing gaps in the adoption, implementation, and enforcement of evidence-based demand-reduction policies is vital to ending the global tobacco epidemic.

Taxation is one of the most effective tobacco control policies available to countries. Increasing taxes decreases demand by reducing the affordability of tobacco products. As income and purchasing power increase, particularly in rapidly developing countries, consistent increases in tobacco taxes to reduce affordability are necessary for this fiscal policy to remain potent. Yet, between 2008 and 2018, the affordability of cigarettes decreased in only 33% of low-income countries compared with in 38% of middle-income countries and 72% of high-income countries. Only one low-income country, Madagascar, taxes tobacco at the rate recommended by the WHO MPOWER framework. Low-income and middle-income countries face the additional challenge of population growth expanding their smoking population. Tobacco taxation is a highly cost-effective measure, and when combined with a progressive approach to redistributing revenue from taxation to tobacco control programmes, health care, and other social support services, can greatly reduce the prevalence of smoking and substantially improve population health.

With 1·14 billion current smokers globally in 2019, increasing cessation rates among current smokers can yield massive health gains. We estimated that fewer than 15% of deaths attributable to smoking tobacco use in 2019 occurred among former smokers aged 30 years and older, despite former smokers comprising approximately a third of the ever smoker population aged 30 years and older. Consistent with other studies, we found in our meta-analyses of risk reduction among former smokers that cessation shifts smokers into a lower-risk category, with greater reduction in risk for longer durations since cessation. Relative risks of all-cause mortality from long-running cohort studies in the UK and the USA indicate that up to two-thirds of long-term smokers will eventually die of a disease attributable to smoking. These data underscore the importance of adopting policies and interventions that increase rates of cessation.

The results of our study must be interpreted in the context of several limitations. First, data on smoking tobacco use are self-reported, which might lead to underestimates in demographic groups with low social acceptability of smoking, particularly among females in Asia and Africa. Second, the scope of our study focuses on smoked tobacco products, and does not include smokeless tobacco products, e-cigarettes, heated tobacco products, or other electronic nicotine delivery systems. Incorporating the health effects of the array of emerging electronic nicotine delivery systems, including both potential benefits and potential harms, is becoming increasingly important. Additionally, our analysis focuses on the health effects of primary smoking of tobacco and does not include additional harms due to second-hand smoke. Third, we converted non-cigarette smoked tobacco products to cigarette-equivalents on the basis of the weight of tobacco. Conversion on the basis of health effect equivalencies would be more accurate, but a paucity of evidence on the health effects of non-cigarette tobacco products presents challenges to this alternative approach. Fourth, the optimal lag-time between exposure and outcome exceeded 10 years for five outcomes (ischaemic heart disease, lower respiratory tract infections, aortic aneurysm, peripheral artery disease, and peptic ulcer disease). Due to the paucity of data on smoking patterns before 1980, we were restricted to using a maximum lag-time of 10 years. Fifth, the rate of risk reduction among former smokers probably varies by smoking intensity. Although we captured differences in the level of risk, we did not capture differences in the rate of risk reduction in our estimates. Despite these limitations, our results are broadly consistent with previous estimates that use different methods with a different set of limitations.

Smoking remains a defining challenge in global health. Governments, and particularly ministers of health, face substantial obstacles ranging from population growth, to pressure from the tobacco industry, to competing health and political priorities. Nevertheless, it is increasingly important for all countries to adopt, implement, and enforce comprehensive packages of evidence-based tobacco control policies. The current level of tobacco control policy implementation is insufficient in many countries around the world. With more than 1 billion people smoking tobacco globally as of 2019, the annual death toll, economic costs, and burden to health systems caused by smoking will increase in the years to come unless countries take swift and strong action to substantially reduce their smoking rates.
Forensic Medicine and Toxicology (Prof V C Nayak MD), Manipal Academy of Higher Education, Manipal, India; Department of Forensic Science (A D Badwey MSc, N Kapoor MSc), Government Institute of Forensic Science, Nagpur, India; Unit of Biochemistry (A A Baig PhD), Faculty of Business and Management (M A Riaz Mcom), Universiti Sultan Zainal Abidin (Sultan Zainal Abidin University, Kuala Terengganu, Malaysia; Department of Anaesthesiology (M Bakhsheei MD), Department of Cardiology (B Naghshtabazi MD), Hamadan University of Medical Sciences, Hamadan, Iran; Department of Hypertension (Prof M Banach PhD), Medical University of Lodz, Lodz, Poland; Polish Mothers’ Memorial Hospital Research Institute, Lodz, Poland (Prof M Banach PhD), Department of Non-communicable Diseases (P C Banik MPhil), Bangladesh University of Health Sciences, Dhaka, Bangladesh; School of Psychology (Prof S L Barker-Collo PhD), University of Auckland, Auckland, New Zealand; Heidelberg Institute of Global Health (HIGH) (Prof T W Bärnighausen MD, S Chen DSc, S Mohammed PhD), Department of Ophthalmology (Prof J B Jonas MD, S Panda Jonas MD), Heidelberg University, Heidelberg, Germany; T H Chan School of Public Health (Prof T W Bärnighausen MD, I Yunusa PhD), Center for Primary Care (S Basu PhD), Department of Global Health and Social Medicine (A W Eagan MSW), Department of Internal Medicine (N Rajai MD), Division of General Internal Medicine (Prof A Sheikh MD), Harvard University, Boston, MA, USA; Clinical Sciences Department (H J Barsoum), Department of Family and Community Medicine (B Sadik PhD), University of Sharjah, Sharjah, United Arab Emirates; School of Public Health (S Basu PhD), F Filippidis PhD), Department of Primary Care and Public Health (J Car PhD, F Greaves PhD, Prof A Majeed MD, R Palladino MD), Imperial College Business School (D Kusuma DSc), Imperial College London, London, UK; Health Human Resources Research Center (M Bayati PhD), Department of Epidemiology (M Dianatinasab MSc), Non-communicable Disease Research Center (Prof R Malekzadeh MD, S G Sepanlou MD), Department of Parasitology and Mycology (Prof R Pakshir PhD), Shiraz University of Medical Sciences, Shiraz, Iran; Department of Psychiatry (Prof S Bazargan-Hejazi BE), Charles R Drew University of Medicine and Science, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences (Prof S Bazargan-Hejazi BE), University of California Los Angeles, CA, USA; Social Determinants of Health Research Center (M Behzadifar PhD), Lorestan University of Medical Sciences, Khoramabad, Iran; Department of Public Health (T T Bekuma MPH), Wollega University, Nemekite, Ethiopia; Nuffield Department of Population Health (T A Bennett PhD, B Lacey PhD), University of Oxford, Oxford, UK; Department of Internal Medicine (J M Benessa PhD, Prof A R Bruni PhD, A C Goulart PhD), Center for Clinical and Epidemiological Research (A C Goulart PhD, I S Santos PhD), University of São Paulo, São Paulo, Brazil; Thoracic Surgery (K S S Berfield MD), Department of Veterans Affairs, Seattle, WA, USA; Department of Social and Clinical Pharmacy (A S Bhagavathula PharmD), Charles University, hradeč Kralova, Czech Republic; Institute of Public Health (A S Bhagavathula PharmD, I Elbarrar DrPH, Prof S M Shah PhD), United Arab Emirates University, Al Ain, United Arab Emirates; Department of Anatomy (Prof N Bhardwaj MD), Government Medical College Pali, Pali, India; Department of Community Medicine and Family Medicine (P Bhadrava MD), School of Public Health (P Bhadrava MD), Department of Forensic Medicine and Toxicology (T Kanchan MD), Department of Surgical Oncology (Prof S Misra MCh), All India Institute of Medical Sciences, Jodhpur, India; Department of Statistical and Computational Genomics (K Bhattacharyya MSc), National Institute of Biomedical Genomics, Kalyani, India; Department of Statistics (K Bhattacharyya MSc), University of Calcutta, Kolkata, India; Institute of Soil and Environmental Sciences (S Bibi PhD, S Ullah PhD), University of Agriculture, Faisalabad, Pakistan; Social Determinants of Health Research Center (T A Bihani PhD), Babol University of Medical Sciences, Babol, Iran; Department of Health Behaviour, Environment and Social Medicine (B Bintoro MD), Gadjah Mada University, Sleman, Indonesia; Department of General Surgery and Medical-Surgical Specialties (Prof A Biondi PhD, M Vacante PhD), University of Catania, Catania, Italy; Department of Public Health (S Birara MPH), Samara University, Samara, Russia; Department of Epidemiology (D Brathwaite PhD), Pharmacology and Drug Policy Department (S G Nduaghu PhD), University of Florida, Gainesville, FL, USA; Cancer Population Sciences Program (D Brathwaite PhD), University of Florida Health Cancer Center, Gainesville, FL, USA; Division of Clinical Epidemiology and Aging Research (Prof H Brenner MD), German Cancer Research Center, Heidelberg, Germany; School of Public Health and Health Systems (Z A Butt PhD), University of Waterloo, Waterloo, ON, Canada; Al Shifa School of Public Health (Z A Butt PhD), Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan; Institute of Microengineering (F Caetano dos Santos PhD), Federal Polytechnic School of Lausanne, Lausanne, Switzerland; Internal Medicine Department (Prof L A Cama MD), Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Board of Directors (Prof L A Cama MD), Argentine Society of Medicine, Buenos Aires, Argentina (Prof P R Valdez MEd); Centre for Population Health Sciences (J Car PhD), Nanyang Technological University, Singapore; Department of Health Care (Prof R Cárdenas DSc), Metropolitan Autonomous University, Mexico City, Mexico; Oncological Network, Prevention and Research Institute (G Gorini MD), Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy (G Carreras PhD); College of Medicine (J Chang PhD), National Taiwan University, Taipei, Taiwan; Department of Nursing (J J Barsoum), Department of Family and Community Medicine (J Car PhD), National Taiwan University, Taipei, Taiwan; Center for Biomedicine and Community Health (D Chiu PhD), VNU-International School, Hanoi, Vietnam; Department of Health Informatics (S Chung PhD), Department of Epidemiology and Public Health (Prof M Kivimäki MD), Institute of Cardiovascular Science, Imperial College School of Medicine, London, London, UK; Health Data Research UK, London, UK (S Chung PhD); Department of Public Health (Prof M Cirillo MD, R Palladino MD), University of Naples Federico II, Naples, Italy; Research Unit on Applied Molecular Biosciences (UCIBIO) (V M Costa PhD, J P Silva PhD), Department of Chemical Sciences (R A S Couto MD), Department of Chemnistry (M Pinheiro PhD), University of Porto, Porto, Portugal; Department of Health Informatics (O Dadras DrPH), Graduate School of Medicine (O Dadras DrPH), Kyoto University, Kyoto, Japan; Faculty of Medicine (Prof A A M Damasceno PhD), Eduardo Mondlane University, Maputo, Mozambique; IRCCS Istituto Ortopedico G. Galeazzi [Galeazzi Orthopedic Institute IRCCS] (G Damianni MD), University of Milan, Milan, Italy; Department of Dermatology (G Damianni MD), Harrington Heart and Vascular Institute (A Guha MD), Case Western Reserve University, Cleveland, OH, USA; Indian Council of Medical Research, New Delhi, India (Prof I. Dandonda MD), Department of Pathology (P Daneshpajouhnejad MD), Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology (P Daneshpajouhnejad MD), Isfahan Cardiovascular Research Institute (Prof N Sarrafzadegan MD), Department of Radiation and Interventional Neuroradiology (O Shafat MD), Isfahan University of Medical Sciences, Isfahan, Iran; Department of Public Health (J Deregge Gela MPH), Ambo University, Ambo, Ethiopia; Health Research Institute (K Davletov PhD), Al Farabi Kazakh National University, Almaty, Kazakhstan; Department of Nursing (G A Dessie MSc), Department of Psychiatry (T B Mossie MSc, M Tareke MSc), College of Medicine and Health Sciences (G W Tsige MPH), Bahir Dar University, Bahir Dar, Ethiopia; Department of Community Medicine (Prof S D Dharmaratne MD), Faculty of Veterinary Medicine and Zootechnics (Prof D Diaz PhD), Autonomous University of Sinaloa, Culliacán Rosales, Mexico; Institute of Health Economics and Technology, Hanoi, Vietnam (T T Do MD); School of Population Health and Environmental Sciences (A Douiri PhD, Y Wang PhD), King’s College London, UK; Preventive Medicine Program (Prof B B Duncan PhD, Prof M Schmidt PhD), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; School of Medicine (Prof A R Duraias PhD), Federal University of Bahia, Salvador, Brazil; Department of Internal Medicine (Prof A R Duraias PhD), Escola Bahiana de Medicina e Saúde Pública (Bahiana School of Medicine and
Surveillance and Health Services Research (F Islam PhD), American Cancer Society, Atlanta, GA, USA; Public Health Department of Social Medicine (Prof H Iso MD), Graduate School of Medicine (Prof K Yamagishi MD), Osaka University, Suita, Japan; Department of Health Management (R Itumalla PhD), University of Hail, Hail, Saudi Arabia; Department of Health Services Research (M Iwagami PhD), Research and Development Center for Health Services (Prof A Maleki PhD), Social Determinants of Health Research Center (Prof D Lopukhov PhD), Department of Epidemiology and Biostatistics (Prof S Jang PhD), Yonsei University, Seodaemun-gu, South Korea; Substance Abuse Prevention Research Center (B Mansouri PhD), Social Development and Health Promotion Research Center (M Mirzaei-Alavijeh PhD), Cardiovascular Research Center (M Nalini MD), Research Center for Environmental Determinants of Health (K Sharif PhD), Department of Health Education and Health Promotion (S Sabahi PhD), Department of Sports Medicine and Rehabilitation (A Soroush MD), Kermanshah University of Medical Sciences, Kermanshah; P (Jha MSC), Dr Baha Saheb Ambedkar Medical College & Hospital, Delhi, India; Department of Community Medicine (R P Jha MSC), Banana's Hindi University, Varanasi, India; Beijing Institute of Ophthalmology (Prof J B Jonas MD), Beijing Tongren Hospital, Beijing, China; Health Services Management Training Centre (T Joo MSC), Semmelweis University, Budapest, Hungary; Institute of Family Medicine and Public Health (M Juriessen PhD), University of Tartu, Tartu, Estonia; School of Public Health (Z Kalur PhD), University College Cork, Cork, Ireland; Sydney Eye Hospital (H Kandel PhD), University of New South Wales, Sydney, NSW, Australia; MRC/CSO Social and Public Health Sciences Unit (S V Katireddy PhD), University of Glasgow, Glasgow, UK; School of Pharmacy (H K Kebede MSC), Department of Psychiatry (M Soboka MSC), Jimma University, Jimma, Ethiopia; Institute for Global Tobacco Control, Baltimore, MD, USA (Prof R D Kennedy PhD); Department of Public Health (A T Kheja MD), Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia; Department of Public Health (Prof J Khubchandani PhD), New Mexico State University, Las Cruces, NM, USA; Department of Preventive Medicine (G Kim PhD), Prof E Park PhD, Institute of Health Services Research (D Lee BS, Prof E Park PhD), Department of Public Health (D Lee BS), Yonsei University, Seoul, South Korea; Big Data Department (Y Kim PhD), National Health Insurance Service, Wonju, South Korea; Department of Nutrition (R W Kimokoti MD), Simmons University, Boston, MA, USA; Department of Public Health (Prof M Kivimäki PhD), University of Helsinki, Helsinki, Finland (T J Meretoja MD); Independent Consultant, Jakarta, Indonesia (S Kosen MD); Kasturba Medical College, Udupi, India (S Koulamne Laxminarayana MD); CIBERSAM (A Koyanagi MD), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain (A Koyanagi MD); Department of Anthropology (K Krishan PhD), Panjub University, Chandigarh, India; University of Environment and Sustainable Development, Somanaya, Ghana (N Kugbey PhD); Department of Community Medicine (N Kumar MD, R Thapar MD), Manipal Academy of Higher Education, Mangalore, India; Faculty of Health and Life Sciences (O P Kurni PhD), Coventry University, Coventry, UK; Department of Medicine (O P Kurni PhD), Department of Psychiatry and Behavioral Neurology (MD), McMaster University, Hamilton, ON, Canada; Faculty of Public Health (D Kusuma DSc), University of Indonesia, Depok, Indonesia; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK (B Lacey PhD); Division of Research (O Lam PhD), Kaiser Permanente, Oakland, CA, USA; Unit of Genetics and Public Health (Prof I Landires MD), Institute of Medical Sciences, Las Tablas, Panama; Ministry of Health, Herrera, Panama (Prof I Landires MD); Department of Medical Research (Prof A Lascu PhD), Faculty of Medicine, Vasile Milea University of Medicine and Pharmacy, Cluj-Napoca, Romania; Department of Management Science and Engineering (T Mavridou PhD), National Technical University of Athens, Athens, Greece; Institute of Medical Science (S Nalini MD), Research Center for Environmental Determinants of Health (K Niroula PhD), National Research Council, Pisa, Italy; Graduate School of Public Health (Y Lee PhD), Ajou University, Suwon-si, South Korea; Center for Youth Substance Abuse Research (J Leung PhD), The University of Sydney, Australia; School of Public Health (Prof H Lin PhD), Zhengzhou University, Zhengzhou, China; School of Public Health (Prof S Linn DrPH), University of Haifa, Haifa, Israel; Institute for Health and Environment (W Liu PhD), Chongqing University of Science and Technology, Chongqing, China; Melbourne School of Population and Global Health (Prof A D Lopez PhD), School of Health Sciences (A Meretoja MD), Department of Pediatrics (Prof C Paton PhD), Department of General Practice (J Zhang MD), University of Melbourne, Melbourne, VIC, Australia; Department of Epidemiology and Evidence Based Medicine (P D Pugh PhD), Department of Epidemiology and Evidence-Based Medicine (R V Polin PhD), I M Sechener First Moscow State Medical University, Moscow, Russia; Institute of Nutritional Sciences (Prof S Lorkowski PhD), Friedrich Schiller University Jena, Jena, Germany; Competence Cluster for Nutrition and Cardiovascular Health (nurtriCARD), Jena, Germany (Prof S Lorkowski PhD); Environmental Health Research Center (Prof A Maleki PhD), Social Determinants of Health Research Center (G Moradi PhD), Department of Epidemiology and Biostatistics (G Moradi PhD), Kurdistan University of Medical Sciences, Sanandaj, Iran; Department of Maternal and Child Nursing and Public Health (Prof D C Malta PhD), Federal University of Minas Gerais, Belo Horizonte, Brazil; Institute for Social Science Research (A A Mamun PhD), The University of Queensland, Indooroopilly, QLD, Australia; Department of Psychiatry (N Manjunatha MD), National Institute of Mental Health and Neurosciences, Bengaluru, India; Psychiatry Department (J Martinez-Raga PhD), Hospital Universitario Doctor Peset, Valencia, Spain; Department of Medicine (J Martinez-Raga PhD), University of Valencia, Valencia, Spain; Indonesian Public Health Association, Surabaya, Indonesia (S Martini PhD); Institute of Population Health Sciences (M R Mathur PhD), University of Liverpool, Liverpool, UK; Department of Dentistry (C E Medina-Solis MSC), Autonomous University of Hidalgo State, Pachuca, Mexico; Ministry of Health, Kathmandu, Nepal (S Mehata PhD); Peru Country Office (W Mendoza MD), United Nations Population Fund (UNFPA), Lima, Peru; Neurology Unit (A Meretoja MD), Breast Surgery Unit (T J Meretoja MD), Helsinki University Hospital, Helsinki, Finland; Center for Innovation in Medical Education (B Mizagowski MD), Pomeranian Medical University, Szczecin, Poland (B Mizagowski MD); Woman-Mother-Child Department (I Michalek PhD), Lausanne University Hospital, Lausanne, Switzerland; Pacific Institute for Research & Evaluation, Calverton, MD, USA (T R Miller PhD); Internal Medicine Programme (Prof E M Mirrakhimov PhD), Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan; Department of Atherosclerosis and Coronary Heart Disease (Prof E M Mirrakhimov PhD), National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan; Research Center for Biochemistry and Nutrition in Metabolic Diseases (H Mirzaei PhD), Kashan University of Medical Sciences, Kashan, Iran; Department of Epidemiology and Biostatistics (A Mohammad-Hafshejani PhD), Shahrekord University of Medical Sciences, Shahrekord, Iran; Health Systems and Policy Research Unit (S Mohammad PhD), Department of Surgery (M A Tolani FWACS), Ahmadu Bello University, Zaria, Nigeria; Clinical Epidemiology and Public Health Research Unit (L Monasta DSc, L Rodnani PhD), Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; World Health Organization (WHO) Centre on eHealth (M Moni PhD), School of Public Health and Community Medicine (Prof A E Schutte PhD), Centre for Primary Health Care and Equity (CPFHEC) (F Sitas PhD), University of New South Wales, Sydney, NSW, Australia; School of Nursing and Midwifery (S T Olagunju MD), University of Michigan School of Medicine, Ann Arbor, MI, USA; Department of Epidemiology and Biostatistics (S Mobarik MS, Prof C Yu PhD), School of Medicine (Z Zhang PhD), Wuhan University, Wuhan, China; Department of Pulmonary Medicine (S Nair MD), Government Medical College Trivandrum, Trivandrum, India; Health Action by People,
Articles

(V Y Skryabin MD), Laboratory of Genomics and Genetics (Prof M S Zostrothinzhoi PhD), Moscow Research and Practical Centre on Addictions, Moscow, Russia; Therapeutic Department (A A Skryabina MD), Balashniki Central Hospital, Balashikha, Russia; Hospital Universitario de La Princesa (Princess University Hospital) (Prof J B Soriano MD), Autonomous University of Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERSESP) (Center for Biomedical Research in Respiratory Diseases Network), Madrid, Spain (Prof J B Soriano MD); Institute for Leadership and Health Management (S Soshnikov PhD), Sekhenov First Moscow State Medical University, Moscow, Russia; Guild York Medical School (I N Sooyi PhD), University of Hull, Hull City, UK; Division of Community Medicine (C T Sreeramareddy MD), International Medical University, Kuala Lumpur, Malaysia; Department of Medicine (P Steiroplinous MD), Democritus University of Thrace, Alexandroupolis, Greece; Department of Cardiology (S Stortcky MD), University of Bern, Bern, Switzerland; Schiller Institute (Prof K K Tshidoo MD), Boston College, Boston, MA, USA; Barcelona Institute for Global Health, Barcelona, Spain (Prof K K Tshidoo MD); Department of Statistics (R Sulankachi Abdulkuder MD), Manonmaniam Sundaranar University, Alibekapati, India; National Institute of Epidemiology (R Sulankachi Abdulkuder MD), Indian Council of Medical Research, Chennai, India; Norwegian Institute of Public Health, Bergen, Norway (G Stolho PhD); Cancer Control Center (T Tabuchi MD), Osaka International Cancer Institute, Osaka, Japan; School of Dentistry and Oral Health (S K Tadakamadla PhD), Griffith University, Gold Coast, QLD, Australia; Department of Pharmacy (B W Tiddey MPH), Arbanmich College of Health Sciences, Arba Minch, Ethiopia; Department of Population Science and Human Resource Development (Prof M I Tareque PhD), University of Rajshahi, Rajshahi, Bangladesh; Research and Development Center for Humanities and Health Management (I U Tariqin PhD), National Institute of Health Research & Development, Jakarta, Indonesia; Department of Public Health and Community Medicine (Prof K R Thaknapped MD), Central University of Kerala, Kasaragod, India; Faculty of Biomedical Engineering (A Tichopad PhD), Czech Technical University, Prague, Czech Republic; 1st Department of Ophthalmology (Prof F Topozzi MD), Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Pathology and Legal Medicine (M R Tovani-Palone PhD), University of São Paulo, Ribeirão Preto, Brazil; moderate, London, UK (M R Tovani-Palone PhD); Department of Health Economics (B X Tran PhD), Hanoi Medical University, Hanoi, Vietnam; Department of Community Medicine (J P Traphaty MD), All India Institute of Medical Sciences, Nagpur, India; Department of Vascular Surgery (N Tilimpairi MD), Ludwig Maximilians University, Munich, Germany; Department of Cardiovascular, Endocrine-metabolic Diseases and Aging (B Umil PhD), National Institute of Health, Rome, Italy; Velez Sarsfield Hospital, Buenos Aires, Argentina (Prof P R Valdez MD); Laboratory of Toxicology (C Vardavas PhD), University of Crete, Heraklion, Greece; Epidemiology Department (Prof P Varona Perez MD), National Institute of Hygiene, Epidemiology and Microbiology (INHEM), Havana, Cuba; UKK Institute, Tampere, Finland (Prof T J Vaisankari MD); Raffles Neuroscience Centre (Prof N Venketsubramanian MBBS), Raffles Hospital, Singapore; Yong Foo Lin School of Medicine (Prof N Venketsubramanian MBBS), National University of Singapore, Singapore; Department of Community Medicine and Family Medicine (M Verma MD), All India Institute of Medical Sciences, Bathinda, India; Department of Psychopharmacology (M V Vetvoda PhD), Pavlov University, Saint Petersburg, Russia; Faculty of Information Technology (B Vo PhD), Ho Chi Minh City University of Technology (HUTECH), Ho Chi Minh City, Vietnam; Federation University Medical College (Prof Y Waheed PhD), Foundation University Islamabad, Islamabad; Pakistan; Demographic Change and Aging Research Area (A Weedecker PhD), Federal Institute for Population Research, Wiesbaden, Germany; Department of Community Medicine (N D Wankaramishe MD), Rajarata University of Sri Lanka; Anuradhapura, Sri Lanka; Division of Cardiology (S Yandrapalli MD), New York Medical College, Valhalla, NY, USA; Division of Cardiology (S Yandrapalli MD), Westchester Medical Center, Valhalla, NY, USA; Department of Public Health (Prof H Yatsuha MD), Fujita Health University, Toyoake, Japan; Department of Public Health and Health Systems (Prof H Yatsuha MD), Nagoya University, Nagoya, Japan; Health Services Management Research Center (Y Yazidi-Feyzabadi PhD), Department of Health Management, Policy, and Economics (Yazerdi-Feyzabadi MD); Kerman University of Medical Sciences, Kerman, Iran; Human Anatomy Unit (M Z Yimmer MSc), Wollo University, Dessie, Ethiopia; Department of Neuropsychopharmacology (N Yonemoto MPH), National Center of Neurology and Psychiatry, Kodaira, Japan; Department of Public Health (N Yonemoto MPH); Uptenndo University, Germany; Department of Health care Management and Economics (H Yusefzadeh PhD), Urmia University of Medical Science, Urmia, Iran; School of Rehabilitation Therapy (M S Zaman MSc), Queen’s University, Kingston, ON, Canada; Unit on Child & Adolescent Health (Prof J H Zar PhD), Medical Research Council South Africa, Cape Town, South Africa; Addology Department (Prof M S Zostrothinzhoi PhD), Pediatrics Department (A Zostrothinzhoi PhD), Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Victorian Comprehensive Cancer Centre, Melbourne, VIC, Australia (J Zhang MD); Health Technology Assessment Unit (Y H Zuniga BS), Department of Health Philippines, Manila, Philippines; #MentalHealthPH, Quezon City, Philippines (Y H Zuniga BS).

Declaration of interests

VA reports personal fees from Bayer Healthcare, Boehringer Ingelheim/Lilly alliance, Bristol Myers Squibb/Pfizer alliance, and Novo Nordisk outside of the submitted work. RA reports consultancy and speakers’ fees from UCB, Sanoz, AbbVie, Zentiva, Teva, Loparopch, CEGEDIM, Angelini, Bieessen Pharma, Hoffig, AstraZeneca, and Stada outside of the submitted work. BeA reports personal fees from Australian Institute of Sports; non-financial support from Zyus Duldia; and grants and non-financial support from Natural Remedies outside of the submitted work. FG was employed by Public Health England during the conduct of the study, which does not necessarily endorse this study. GH reports personal fees from the American Heart Association outside of the submitted work. SMSI reports grants from National Heart Foundation of Australia and from the Australian National Health and Medical Research Council (NHMRC) outside of the submitted work. SVK reports grants from Chief Scientist Office and UK Medical Research Council during the conduct of the study. KK reports non-financial support from UGC Centre of Advanced Study (CAS II), Department of Anthropology, Panjab University, Chandigarh, India, outside of the submitted work. ST reports personal fees from Akera Therapeutics, Amedes, AMGEN, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo, Lilly, MSD Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Synlab, Unilever, and Upfield, and non-financial support from Preventics outside of the submitted work. WM is Program Analyst in Population and Development at the UN Population Fund-UNFPA Office in Peru, which does not necessarily endorse this study. TRM reports contracts from Gov’t Plaintiff Lawyers, JUUL, outside of the submitted work. BoN reports personal fees from AstraZeneca and Bayer, outside of the submitted work. SimS reports grants, personal fees, and non-financial support from Abbott and Novartis; personal fees and non-financial support from Allergan-Abbvie, AstraZeneca, and Teva; and personal fees from Eli Lilly and Novo Nordisk outside of the submitted work. AES reports personal fees from Takeda, Novartis, Servier, and Omron Healthcare outside of the submitted work. JAS reports consultancy fees from Crealta/Horizon, Medisys, Fidia, Two Labs Inc, Adept Field Solutions, Clinical Care options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Sphera, MedIQ, UBM, Trio Health, Medscope, WebMD, Practice Point communications, the National Institutes of Health, and the American College of Rheumatology; payment for lectures including service on Simply Speaking speaker’s bureau; and stock ownership in TPT Global Tech, Vaxart pharmaceuticals, and Charlotte’s Web Holdings. JAS previously owned stock options in Amarin, Viking, and Moderna pharmaceuticals; held placement on the steering committee of OMERACT, an international organisation that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies; serves on the US Food and Drug Administration–Arthritis Advisory Committee; is a member of the Veterans Affairs Rheumatology Field Advisory Committee; and is the editor and the director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis.
DJS reports personal fees from Lundbeck, Takeda, Johnson & Johnson, and Servier outside of the submitted work. SJIS reports grants from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott; and personal fees from Boston Scientific, Telefex, and BTG outside of the submitted work. JS reports ownership in companies providing services to Itrin, Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer, Bayer, Pfizer, and AstraZeneca outside of the submitted work. FT reports grants and personal fees from Novartis, Thé, Alexion, Pfizer; and grants from Bausch & Lomb; and personal fees from Allergan, Omikron, and Santen outside of the submitted work. All other authors declare no competing interests.

Data sharing
To download the data used in these analyses, please visit the Global Health Data Exchange GBD 2019 website.

Acknowledgments
SheMA acknowledges support from Monash University, VIC, Australia. SyMa would like to acknowledge the International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia and Department of Health Policy and Management, Faculty of Public Health, Kuwait University for the approval and support to participate in this research project. MarzA, AdP, and CH are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation (CNS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084). TWB was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. SB-H was supported by National Institutes of Health (NIH) National Center for Advancing Translational Science (NCATS) UCLA (CTSI grant number ULITR001883). DAB research receives support from the Oxford National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). VMC acknowledges her grant (SFRH/BPD/100001/2015), received by Portuguese national funds through Fundação para a Ciência e Tecnologia (FCT), IP, under the Norma Transitoriá DL57/2016/CP1134/CT0006. AD acknowledges funding support from the NIHR Applied Research Collaboration (ARC) South London at King’s College Hospital NHS Foundation Trust and the Royal College of Physicians, as well as the support from the NIHR BRC based at Guy’s and St Thomas’ Hospital Trust and King’s College London. MMS-M acknowledges the support of the Ministry of Education Science and Technological Development of the Republic of Serbia; and the National University of Medicine, Nis, Serbia. AMS acknowledges the support of the Ministry of Education Science and Technological Development of the Republic of Serbia; and the Medical Research Council (MRC) UK. MEK was supported by FIU University Graduate School based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. CH and AdP are partially supported by a grant of the Warwick; and the NIHR Global Health Group on Addressing Smokeless Tobacco Use and Future Research Collaborations West Midland; the NIHR Global Health Research Unit on Improving Health in Slums at the University of Warwick; and the NIHR Global Health Group on Addressing Smokeless Tobacco Use & Building Research Capacity in South Asia at the University of York. CH and AdP are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation (CNS-UEFISCDI, project number PN-III-P2-2.1-SOL-2020-2-0351). JYI is supported by UNC’s Cancer Care Quality Training 2T32CA116319-11. SMSI is funded by the National Heart Foundation of Australia and NHMRC. MihJ acknowledges funding through grant 2T32CA116339-11. SMSI is funded by the National Heart Foundation of Australia and NHMRC. MihJ acknowledges funding through grant 2T32CA116339-11. CH and AdP are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation (CNS-UEFISCDI, project number PN-III-P2-2.1-SOL-2020-2-0351).

For the Global Health Data Exchange GBd 2019 website see http://ghdx.healthdata.org/ gbd-2019/data-input-sources

References
1 GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223–49.
2 Goodchild M, Nargis N, Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control 2018; 27: 58–64.
3 Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med 2014; 370: 60–68.
4 US National Cancer Institute, WHO. Monograph 21. The economics of tobacco and tobacco control. NIH Publication No. 16-CA-8029A, Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 2016. https://cancercontrol.cancer.gov/sites/default/ files/2020-06/m21_complete.pdf (accessed April 9, 2021).
5 Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 2014; 311: 164–71.
6 Lightwood J, Glazte SA. Smoking behavior and healthcare expenditure in the United States, 1992–2009: panel data estimates. PLoS Med 2016; 13: e1002020.
7 van Meijgaard J, Fielding JE. Estimating benefits of past, current, and future reductions in smoking rates using a comprehensive model with competing causes of death. Prev Chronic Dis 2012; 9: E122.
8 WHO. WHO framework convention on tobacco control. Geneva: World Health Organization, 2005.
9 Chung-Hall J, Craig L, Gravel S, Sansone N, Fong GT. Impact of the WHO FCTC over the first decade: a global evidence review prepared for the Impact Assessment Expert Group. Tob Control 2019; 28 (suppl 2): ii19–28.
10 WHO. WHO report on the global tobacco epidemic 2019: offer help to quit tobacco use. Geneva: World Health Organization, 2019. https://www.who.int/teams/handle/tobacco-promotion/tobacco-control/ who-report-on-the-global-tobacco-epidemic-2019 (accessed April 28, 2021).
11 WHO Regional Office for South-East Asia. Tobacco control for sustainable development. New Delhi: World Health Organization, Regional Office for South-East Asia, 2017. https://apps.who.int/iris/handle/10665/255509 (accessed April 9, 2021).
12 Beagleshole R, Bonita R, Alleyne G, et al. UN High-Level meeting on non-communicable diseases: addressing four questions. Lancet 2011; 378: 469–55.
13 Bennett JE, Kontis V, Mathers CD, et al. NCD countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. Lancet 2019; 394: 918–34.
14 Sacco RL, Roth GA, Reddy KS, et al. The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation. Circulation 2016; 133: e674–90.
15 Glantz S, Gonzalez M. Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet 2012; 379: 1269–71.
16 Beaglehole R, Bonita R, Horton R, et al. Measuring progress on NCDs: one goal and five targets. Lancet 2012; 380: 1283–85.
17 Bilano V, Gilmour S, Moffett T, et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. Lancet 2015; 385: 966–76.
18 Doll R. On the aetiology of cancer of the lung. Acta Unio Int Contra Cancrum 1951; 7: 39–50.
19 Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA 2014; 311: 183–92.
20 GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017; 389: 1885–906.
21 Hoffman SJ, Mammone J, Rogers Van Katwyk S, et al. Cigarette consumption estimates for 71 countries from 1970 to 2015: systematic collection of comparable data to facilitate quasi-experimental evaluations of national and global tobacco control interventions. BMJ 2019; 365: l2231.
22 Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436–42.
23 Petro R, Lopez AD, Boreham J, Thun M, Heath C Jr. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992; 339: 1268–78.
24 Erzati M, Lopez AD. Measuring the accumulated hazards of smoking: global and regional estimates for 2000. Tob Control 2003; 12: 79–85.
25 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet 2016; 388: e19–23.
26 GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Public Health 2021; published online May 27. https://doi.org/10.1016/S2468-2667(21)00065-7.
27 GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1923–94.
28 Foreman KJ, Lopez Lozano R, Lopez AD, Murray CJL. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr 2012; 10: 1.
29 Flaxman AD, Vos T, Murray CJL. An integrative metaregression framework for descriptive epidemiology. University of Washington Press. https://uwpress.uw.edu/book/9780295991849/an-integrative-metaregression-framework-for-descriptive-epidemiology (accessed June 17, 2020).
30 Reitsma M, Kendrick P, Anderson J, et al. Reexamining rates of decline in lung cancer risk after smoking cessation. A meta-analysis. Ann Am Thorac Soc 2020; 17: 1126–32.
31 GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204–22.
32 Hanley JA. A heuristic approach to the formulas for population attributable fraction. J Epidemiol Community Health 2001; 55: 508–14.
33 Doll R, Hill AB. Smoking and carcinoma of the lung: preliminary report. BMJ 1950; 2: 739–48.
34 Gravely S, Giovino GA, Craig L, et al. Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. Lancet Public Health 2017; 2: e166–74.
35 Hammond D. Health warning messages on tobacco products: a review. Tob Control 2011; 20: 327–37.
36 Henrissen L. Comprehensive tobacco marketing restrictions: promotion, packaging, price and place. Tob Control 2012; 21: 147–53.
37 Levy DT, Tarn J, Xoo C, Fong GT, Chaloupka F. The impact of implementing tobacco control policies: the 2017 tobacco control policy scorecard. J Public Health Manag Pract 2018; 24: 448–57.
38 Chaloupka FJ, Straif K, Leon ME. Effectiveness of tax and price policies in tobacco control. Tob Control 2011; 20: 235–38.
39 WHO. Earmarked tobacco taxes: lessons learnt from nine countries. Geneva: World Health Organization, 2016. https://apps.who.int/iris/bitstream/handle/10665/206007/9789241510424_eng.pdf?sequence=1 (accessed April 9, 2021).
40 Dresler CM, León ME, Straif K, Baan R, Secretan B. Reversal of risk of smoking. Lancet 2006; 368: 348–49.
41 Pirie K, Petro R, Reeves GK, Green J, Berzl V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the U.K. Lancet 2013; 381: 133–41.
42 Doll R, Petro R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004; 328: 1519.
43 Jia P, Ramaanundaraehettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013; 368: 141–50.
44 Jung-Choi K-H, Kangan Y-H, Cho H-J. Hidden female smokers in Asia: a comparison of self-reported with cotinine-verified smoking prevalence rates in representative national data from an Asian population. Tob Control 2012; 21: 536–42.